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Abstract 
Bioactive Nano-Fibrous Scaffolds for Bone and Cartilage Tissue Engineering 
by 
Kai Feng 
 
Chair: Peter X. Ma 
            Scaffolds that can mimic the structural features of natural extracellular 
matrix and can deliver biomolecules in a controlled fashion may provide cells with a 
favorable microenvironment to facilitate tissue regeneration. Biodegradable nanofibrous 
scaffolds with interconnected pore network have previously been developed in our 
laboratory to mimic collagen matrix and advantageously support both bone and cartilage 
regeneration. This dissertation project aims to expand both the structural complexity and 
the biomolecule delivery capacity of such biomimetic scaffolds for tissue engineering. 
We first developed a nanofibrous scaffold that can release an antibiotic 
(doxycycline) with a tunable release rate and a tunable dosage, which was demonstrated 
to be able to inhibit bacterial growth over a prolonged time period.  
We then developed a nanofibrous tissue-engineering scaffold that can release 
basic fibroblast growth factor (bFGF) in a spatially and temporally controlled fashion. In 
a mouse subcutaneous implantation model, the bFGF-releasing scaffold was shown to 
xvi 
 
enhance cell penetration, tissue ingrowth and angiogenesis. It was also found that both 
the dose and the release rate of bFGF play roles in the biologic function of the scaffold. 
After that, we developed a nanofibrous PLLA scaffold that can release both bone 
morphogenetic protein 7 (BMP-7) and platelet-derived growth factor (PDGF) with 
distinct dosages and release kinetics. It was demonstrated that BMP-7 and PDGF could 
synergistically enhance bone regeneration using a mouse ectopic bone formation model 
and a rat periodontal fenestration defect regeneration model. The regeneration outcome 
was dependent on the dosage, the ratio and the release kinetics of the two growth factors.       
Last, we developed an anisotropic composite scaffold with an upper layer 
mimicking the superficial zone of cartilage and a lower layer mimicking the middle zone 
of cartilage. The thin superficial layer was fabricated using an electrospinning technique 
to support a more parallel ECM orientation to the cartilage surface. The lower layer was 
fabricated using a phase-separation technique to support a more isotropic ECM 
distribution. Human bone marrow-derived mesenchymal stem cells (hMSCs) were seeded 
on this complex scaffold and cultured under chondrogenic conditions. The results showed 
that the composite scaffold was indeed able to support anisotropic cartilage tissue 
structure formation.  
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Chapter 1 
Introduction 
 
Background and motivation 
        Organ failure and tissue loss resulting from trauma and diseases remain major 
healthcare challenges in the United States. About one half of the national medical 
spending is attributed to the treatment of organ failure and tissue loss with approximately 
8 million surgeries and 40-90 million hospital days per year. [1-3] Although significant 
advances have been made in medical sciences and technologies, organ failure and tissue 
loss are still treated with transplantation. In 2008, 27,281 organ transplantation 
procedures were performed in the United States, while 100,597 patients were on waiting 
lists for organ transplantation. [4]There is a huge gap between the number of people on 
the waiting list and the available organ number, and many patients on the waiting list 
eventually die because of organ shortage.  Besides donor shortage, there are additional 
problems. For example, bone grafts and metallic/ceramic implants are two major 
treatments to bone loss. In the U.S, approximately 90% of bone grafts are autografts and 
allografts. [5]Donor site morbidity and pathogen transmission are two major drawbacks 
associated with autografts and allografts, respectively. [6] Metallic/ceramic implants are 
different from native bone in structure and mechanical properties, often leading to 
additional bone damage. [7] 
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        Tissue engineering is an interdisciplinary field that applies the principle of 
engineering and life science to aim at constructing biological substitutes to repair 
damaged tissue. In order to achieve satisfactory tissue regeneration, three key issues need 
to be considered: the isolation and cultivation of cells, the use of tissue-inductive 
biomolecules and the placement of cells in suitable scaffolds to support 3-D tissue 
regeneration. [2] In a traditional tissue engineering approach, cells are cultured and 
seeded on a scaffold and then implanted into the defect site to form new tissue. [2] In this 
approach, the cells provide the main source for new tissue regeneration. The scaffolds act 
as three-dimensional matrices for cell growth and degrade away as the tissues are 
regenerated.[8] Despite the encouraging early results[3, 9], the limited number of donor 
cells and low quality of regenerated tissues remained two hurdles in tissue engineering 
approach. [10] Scaffolds are required to provide additional functions besides providing 
structure support and suitable degradation kinetics. Another approach is to implant 
acellular scaffold in the defect site with the capability of delivering appropriate 
biomolecules in a controlled manner, thereby recruiting progenitor cells to the defect site 
and promoting cell proliferation and differentiation, inducing tissue regeneration. [2] 
Factor-releasing scaffolds are gaining popularity and have recently been used along with 
incorporated cells. [11-14]These scaffolds are often called bioactive scaffolds.  [15, 16]         
        The main hypotheses of this thesis are: (1) controlled delivery of  appropriate 
growth factors from nanofibrous scaffold will facilitate angiogenesis and osteogenesis 
leading to high quality bone regeneration; (2) the development of  structural complexity 
in scaffolds to mimic complicated natural extracelluar matrices in terms of pore 
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morphology, fiber, size and orientation will facilitate complex tissue regeneration. The 
specific Aims of this thesis are listed below:     
        1. To fabricate 3D nanofibrous scaffolds with the capacity of delivering a single 
biomolecule such as an antibiotic or growth factor, characterize the in vitro release 
profiles, and evaluate the biological function of these released biomolecules both in vitro 
and in vivo. Specifically, we focus on doxycycline-delivering scaffold to inhibit bacterial 
growth in vitro and basic fibroblast growth factor (bFGF)-delivering scaffold to promote 
tissue ingrowth and angiogenesis in vivo. 
        2. To fabricate 3D nanofibrous scaffold with capacity of delivering two growth 
factors and evaluate the effects on bone tissue regeneration in vivo. Specifically, we 
focus on scaffolds releasing both bone  morphogenetic protein 7 (BMP-7) and platelet-
derived growth factor (PDGF). The biological function of these scaffolds in bone 
regeneration will be first examined in a mouse subcutaneous implantation model. Several 
scaffolds with different dosage ratios and release rates of BMP-7 and PDGF will be 
implanted and the in vivo bone regeneration will be evaluated to determine the optimal 
release rate and dosage for each growth factor to achieve the most synergetic effects. 
Then, the biological effectiveness of the scaffolds with the optimal dosage ratio and 
release rates of two growth factors will be evaluated using a periodontal bone defect 
repair model. 
        3. To fabricate a 3D nanofibrous composite scaffold containing two layers with 
different fiber and pore morphologies and examine the effect of this novel scaffold on 
complex tissue regeneration in vitro. Specifically, we will focus on the combination of 
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electrospinning and phase separation techniques to create composite scaffolds and 
examine the effects on chondrogenesis to zonal structure formation in vitro. 
 
Dissertation overview 
        Chapter 2 provides a general literature review of the nanostructured biomaterials 
used in tissue regeneration. Emphasis is placed on two aspects: (1) nanofibrous scaffold 
fabrication techniques including electropsinning, self assembly and temperature induced 
phase separation, (2) growth factor delivery in various 3-D scaffolds.  
        Chapter 3 begins the research part of this thesis with the fabrication of novel 
antibacterial nanofibrous PLLA scaffolds. Here, antibiotic doxycycline is incorporated 
into PLGA nanospheres and the spheres are immobilized onto nanofibrous PLLA 
scaffolds. The release profiles of doxycycline from the scaffolds are examined and both 
short term and long term in vitro bacterial inhibition effect of the scaffolds are 
demonstrated.  This work was published in Journal of Controlled Release. [17] 
        Chapter 4 details the development of basic fibroblast growth factor (bFGF)-
containing nanospheres (NS) and their immobilization onto nanofibrous PLLA scaffolds. 
In vitro release profiles of bFGF from different PLGA nanospheres on the scaffolds  are 
determined. Tissue ingrowth and angiogenesis into these scaffolds are studied in a 
subcutaneous implantation model. 
        Chapter 5 develops one single nano-fibrous scaffold capable of delivering two 
different growth factors (BMP-7and PDGF). The fabrication method is described. The 
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ectopic bone formation in scaffolds with different BMP-7/PDGF dosages and release 
rates is examined. Two week and five week bone regeneration on these dual release 
scaffolds is investigated using a rat periodontal defect model.  
        Chapter 6 creates an anisotropic composite scaffold to mimic zonal structure of 
cartilage tissue with a combination of electropinning and phase separation methods. In-
vitro chondrogenesis of human bone marrow-derived mesenchymal stem cells (hMSCs) 
on this scaffold  is studied. 
        The final chapter, chapter 7, summarizes the thesis work with major conclusions and 
discusses some possible future directions related to this dissertation. 
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Chapter 2 
Nanostructured biomaterials and growth factor delivery scaffold 
 
Introduction 
        Tissue engineering and Nanotechnology are two exciting science and engineering 
fields. They are both interdisciplinary among biology, chemistry, physics, material 
science and medical science, etc. Tissue engineering applies the principles of engineering 
and the life science to the fabrication and development of biological alternatives for 
harvested tissues and organ transplantation to restore, maintain or improve tissue function. 
[1] Three important factors exist in tissue engineering: cells, growth factors and 
biomaterials (scaffolds). Because cells need anchorage sites and specific environments 
for growth, biomaterials play a pivotal role in both in-vitro tissue culture and in vivo new 
tissue formation in tissue engineering. [2] They serve as matrices for cellular ingrowth, 
proliferation, differentiation into functional form, and new tissue formation in three 
dimensions and eventually disappear over time. [3, 4] 
        With the advances of nanotechnology, material design can be exploited into the 
nanometer scale(1nm=10-9m) and nano-structured biomaterials begin to emerge.[5] 
Among them, nano-fibrous biomaterials are exciting because their ability to the 
extracellular matrix (ECM), which contains abundant fibrous collagen proteins (50-
500nm) [6-8] that regulates cell morphology, cytoskeletal structure and functionality. [9, 
10] The collagen like fibrillar structure of the nanofibrous biomaterials along with their 
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high surface to volume ratio enhances cell adhesion,[6, 11-13] which in turn improve cell 
migration, proliferation, and differentiated function on these biomaterials. [14-16] 
Therefore, nanostructured biomaterials are becoming increasingly important in tissue 
engineering. 
        Various biomolecules have been successfully delivered from tissue engineering 
scaffolds. Growth factors (GFs) are one important group of such biomolecules. They are 
polypeptides that can modulate cellular growth, proliferation and cellular differentiation 
involved in the regeneration of new tissues. [17, 18]. In order to achieve efficient 
biological functions of GFs, the release of GFs from scaffolds should be in a controlled 
manner to reach suitable therapeutic dosage and duration. [19] The bioactivity of growth 
factors should be preserved after the incorporation within the scaffolds. The release 
should occur over a needed time period and the release should be localized to avoid 
potential side effects.  
        In this chapter we will discuss three cutting edge technologies to fabricate 
nanostructured biomaterials: Self assembly, Electrospinning, Phase separation. We will 
also discuss inorganic/organic nanocomposite biomaterials. Finally we will summarize 
current advances in technologies to incorporate growth factor delivery systems into three 
major types of scaffolds used in tissue engineering application including hydrogel 
scaffold, electrospun scaffold and  three dimension (3D) porous scaffold. 
 
Nanofibrous biomaterials 
Self assembly 
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Molecular self assembly is defined as the spontaneous organization of molecules 
under thermodynamic equilibrium conditions into structurally well-defined and rather 
stable arrangements through a number of noncovalent interactions. [20-23] These 
interactions typically involve secondary bonding.[23]  
Fields, Tirrell and co-workers have designed peptide-amphiphiles (PAs) molecules 
by self assembly to mimic the triple-helix super secondary structure of collagen 
molecules. The PA consists of a α1 (IV) 1263-1277 collagen sequence head group which 
is covalently linked to a mono- or di-alkyl ester lipid tail. [24-28]  Later, Fields and co-
workers also developed a chimeric PA incorporating a 21 residue angiogenesis-inducing 
peptide sequence (SPARC) to enhance cell proliferation and angiogenesis. [29]  
Beyond this single molecular unit, nanofibrous materials can be made by self 
assembly too. Zhang, and co-workers synthesized ionic self-complementary 
oligopeptides with regular alternating ionic hydrophilic and hydrophobic residue peptides, 
which can form stable β-sheets.[30-32] When subjected to monovalent alkaline cations or 
physiological conditions, these oligopeptides can self assemble into macroscopic 
hydrogel structures which contain nanofibers about 10-20 nm in diameter. [33-35] It was 
found out that certain cells can attach to, proliferate and differentiate on this hydrogel. 
[30, 31] 
Stupp and co-workers have synthesized peptide amphiphiles (PA) by living anionic 
polymerization that can self assemble to form nanofiber structure of a hydrogel. [36-38] 
The forming nanofibers have diameter approximately 5-8 nm and length up to several 
micrometers. [36, 37] In these nanofibers, the PA molecules are perpendicular to the fiber 
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axis, which is different from the natural collagen matrix having collagen molecules 
parallel to each other. [39] 
In summary, self assembly peptide systems can generate nanofibers in the lowest 
end of natural extracellular matrix collagen fiber diameter range, while they are either 
single molecules or hydrogels.[39] Some properties need to be improved such as pore 
structure and material degradation rate control, cell-material interaction, mechanical 
strengthening. 
 
Electrospinning 
        “Electrospinning” has existed in the literature for more than 100 years. [40] 
Recently, it has gained much more attention in biomedical engineering due to its ability 
to produce fibers whose diameters can be reduced to nanometer range.   
The basic experimental setup of electrospinning includes: (1) applied voltage (2) 
grounded target collector (3) polymer reservoir with a spinneret. Once the applied 
electrical force overcomes the surface tension of the polymer solution or melt, a charged 
jet forms from the pendent solution surface called “Taylor’s cone” [41] and travels in a 
straight line for a certain distance. Then, an electrically driven bending instability grows 
to cause the jet to bend and follow a whipping and spiraling path, which reduces the jet 
diameter. In the final stage, the solution jet evaporates, solidifies and is collected as a 
non-woven fiber mats on the stationary grounded collector [42-44]or rotating target if 
fiber orientation is needed.[45, 46] 
Several natural biopolymers[46-49]and synthetic biodegradable polymers[50-
56]have been successfully electrospun into nanofibrous scaffolds. The diameters of these 
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electrospun fibers can be down to nanometer size, while electrospun fibers of FDA 
approved biodegradable polymers usually have diameters in micrometer range[50, 52-54, 
56]. However, the porosity of electrospun matrices is usually not very high and the pore 
shape is random.[57] A variety of cells were reported to attach and proliferate well on 
these scaffolds and some have been shown to differentiate into or maintain their 
functional phenotypes as well.[46, 52, 54, 56, 58-61] As fiber diameter decreases, cell 
interaction improves and immune response decreases. [62]  
Though there are some untamed challenges with electrospinning technology such as 
difficulty to control pore size and shape and its low porosity, the simplicity makes it 
widely used to fabricate nanofibrous scaffolds. 
 
Phase separation 
As a scaffold fabrication method, phase separation is a process that a homogenous 
polymer solution system becomes thermodynamically unstable and phase separates into 
two phases in order to lower the system free energy under certain conditions. One phase 
is a polymer rich phase while the other is a polymer lean phase. After the solvent is 
removed, the polymer-rich phase solidifies. 
 Conventional phase separation process though very useful in fabricating porous 
membrane for filtration and separation, is not suitable for tissue scaffold fabrication. [63] 
So, Controlled phase separation, primarily thermally induced phase separation (TIPS) has 
been used to fabricate polymeric scaffolds for tissue engineering. [4, 64-71] Liquid-liquid 
phase separation, one of the TIPS, occurs when the crystallization temperature is much 
lower than the phase separation temperature. Combining liquid-liquid phase separation 
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with gelation process [72, 73], nanofibrous matrices mimicking natural type I collagen 
(Fig.2.1) were fabricated in our lab. The fibers diameters are ranged from 50 to 500 nm 
and the porosity of the matrices can be as high as 98%.[71] The morphology of the 
matrices is mainly determined by gelation condition, [4] while other processing 
parameters such as polymer molecular weight, polymer solution concentration, solvent 
exchange and quenching temperature will also affect the morphology of the matrices. [71]   
Open macropore (>100 µm) structure can be incorporated into nanofibrous matrices by 
combining porogen leaching technique or solid Freeform Fabrication techniques (SFF). 
Five steps are involved in the porogen leaching-phase separation process: Polymer  
dissolution, porogen assembly, polymer solution casting,  phase- separation and gelation, 
porogen leaching. Porogens used in our lab are salt or sugar particle[71, 74], sugar 
fibers[71], sugar microspheres[75-77], paraffin microspheres[66]. These matrices have 
very low density and even higher porosity which contains both open pore structure and 
nanofibrous wall. (Fig.2.2) These macropores in the matrices facilitate cell seeding, cell 
migration inside and neovascularization after in vivo scaffold implantation.  
Solid freeform fabrication (SFF) is a process that uses a computer aided design 
(CAD) program to create 3-D structured objects, while reversed SFF is used to design a 
3-D negative mold which is then created layer-by-layer on a 3-D printer. Due to its ability 
to well control the scaffold geometric parameter such as external shape, pore geometries 
and pore interconnectivity, SFF has become more and more popular in scaffolding 
fabrication nowadays. [78, 79] Combining SFF and TIPS, nano-fibrous scaffold with 
complex geometry mimicking human organ can be fabricated. Nanofibrous human ear 
and mandible segment scaffolds were created from 3-D reconstruction of CT-scans or 
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histological section in our lab (Fig.2.3). Cell studies of MC3T3-E1 preosteoblasts showed 
significant better proliferation and higher expression of osteocalcin and bone sialoprotein 
mRNAs on NF scaffolds. [80]  
Nanofibrous scaffolds have been shown to have better cell attachment than solid-
walled scaffolds due to more cell adhesion proteins absorbance. [81] Osteoblasts were 
cultured on both nanofibrous and solid-walled PLLA scaffolds and cells on nanofibrous 
scaffolds showed higher alkaline phosphatase activity and an earlier and enhanced gene 
expression of the osteoblast phenotype. Biomineralization was 13-fold enhanced on 
nanofibrous scaffolds in terms of calcium content assay. Cell seeded on nanofibrous 
scaffolds sustained expression of α-2 integrin when the formation of collagen fibril by 
osteoblasts was inhibited, while cells seed on solid-walled scaffolds failed to do so. These 
results demonstrated that nanofibrous matrices processes some natural collagen fibers 
property and is a better scaffolding than solid-wall scaffolds for promoting osteoblast 
differentiation and biomineralization.[82] 
        In summary, TIPS does not involve complicated PA synthesis and purification 
processes as in self aasembly, nor does it require any facilities in electrospinning. 
However, it provides a great deal of control and diversity in the nanofibrous biomaterials 
fabricated from external shape to macropore structure and to fiber diameter. Their 
interconnected spherical macro-pore network promotes cell penetration. Their 
nanofibrous architecture mimics natural extracellular matrix to promote cell attachment, 
proliferation, differentiation of multiple cell types. [83-86] With these beneficial features, 
these three dimensional porous scaffolds have found applications in regeneration of 
various tissues. [86-90]  
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Nanocomposite biomaterials 
The combination of improved mechanical properties and biocompatibility is the 
goal of nanocomposite biomaterials design. Bone, one of mineralized tissues in human 
body, is a perfect example of natural nanocomposite with nanometer sized platelike 
apatite crystals dispersed in collagen nanofibrous network. Its good mechanical property 
comes from both the nanometer feature of the collagen fiber and apatite crystal and 
composite organization of these two contents. [91, 92]  
To mimic the nanoscale feature of mineral component of the bone, hydroxyaptite 
nanoparticle(nHAP), which is the major mineral phase in natural bone and has good 
osteoconductivity and bone bonding ability, was precipitated onto collagen to form a 
porous composite scaffold. [93, 94] Interfacial new bone formation by osteoblasts and 
composite degradation were observed on these composite scaffolds. [95, 96] In order to 
avoid pathogen transmission and immunorejection, synthetic biodegradable polymers 
were used as the organic component of the composite instead. By using TIPS, 
nHAP/poly(α -hydroxy acids) composite scaffolds with high porosity (>90%) were 
fabricated. By varying phase separation parameters, different morphology like tubular 
and platelet like can be achieved. If a dioxane/water mixture solvent system was used, 
nHAP-PLLA composite scaffold developed a nanofibrous morphology (shown in Fig 2.4) 
which greatly improve the mechanical properties and protein adsorption capacity of the 
scaffolds. [97] Fibronectin and vitronection adsorption was increased which is very 
important for preventing apatotic cell death in these composite scaffolds. [98] It is 
believed that nHAP increased hydrophilicity, surface roughness and total surface area 
which altogether increase protein adsorption and osteoblast adhesion. [99-101] When 
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macropores were introduced into the scaffold, bone-like apatite deposited onto the 
composite scaffold in a simulated body fluid (SBF) (Fig.2.5). The resulting composite 
scaffolds mimics bone matrix and is desirable for bone tissue engineering. [75] 
 
Growth factor delivery scaffold 
Growth factor delivery from hydrogel scaffold 
        Hydrogel scaffold are frequently used to engineer highly metabolic soft tissues, for 
which the load bearing capacity is less demanding but the high permeability of oxygen 
and nutrients are desirable. [102, 103] 
        Four major techniques have been applied to deliver growth factors from hydrogel 
scaffolds including: direct incorporation, microparticle encapsulation, covalent 
attachment and enzymatically cleavable tether attachment. [104]  
        The typical release profile of direct incorporation of growth factors into hydrogels 
consists of  a rapid burst release during hydrogel initial swelling phase followed by an 
extended release of protein retarded by hydrogel polymer crosslink network. [105] Since 
a hydrogel contains more than 90% water in weight, the diffusion of incorporated growth 
factors is mainly determined by the growth factor size relative to chemical or physical 
crosslink density between polymer chains. [102, 106] Several attempts have been made to 
adjust crosslink density to alter these release profiles. [107-110] A slower release rate can 
be achieved by introducing charged polymers such as gelatin to interact with the 
incorporated growth factor (e.g., vascular endothelial growth factor, VEGF) via 
oppositely charged functional groups. [111] Concerns for this approach include the 
denature of growth factors due tochemical cross-linking if they are loaded into a hydrogel 
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before crosslinking or the uneven distribution of the growth factors if they are loaded into 
hydrogel after the cross-linking. [104] 
        Microparticle encapsulation system made from hydrophobic non-swelling 
polymers[112], solid lipids[113], hydrophilic polymers[105, 114]were incorporated into 
hydrogel system to further alter the release profile of growth factor from hydrogel 
scaffold.  Transforming growth factor-beta-1 (TGF-β1) was encapsulated into hydrophilic 
cross-linked gelatin microparticles incorporated into hydrogels. The growth factor release 
profile depends on the degradation of the used micropartiles, which allow multiple 
growth factors to be released at distinct release rates by using different gelatin 
microparticles. [115] 
        Besides, growth factors can also be incorporated into hydrogels by covalent 
attachment [116, 117] and enzymatically cleavable tether attachment. [118, 119] In one 
example, basic fibroblast growth factor (bFGF) was successfully covalent bonded to PEG 
hydrogel. When covalently immobilized bFGF gradient was introduced, cells on the 
hydrogel aligned along the direction of increasing bFGF concentration. [116] These 
designed hydrogels with attached growth factors will be useful in many tissue 
engineering applications, while concerns about the stability of the attached growth factors 
remains. [104] 
 
Growth factor delivery from electrospun scaffold 
        Due to their wide variety of material choices and fabrication simplicity, electrospun 
scaffolds have been applied in multiple types of tissues regeneration. [120-124]However, 
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this technique remains difficult to create macro-pore network and complex 3D shapes for 
large size tissue regeneration. [125-127] 
        In general, four major techniques have been used to incorporate growth factors into 
electrospun scaffolds, including physical adsorption [128, 129], blend electrospinning 
(emulsion electrospinning) [129-132], coaxial electrospinning [131, 133, 134], and 
covalent immobilization[135].  
        Physical adsorption is the easiest way to load growth factors into an electrospun 
scaffold, which is simply dip the scaffold into an aqueous growth factor aqueous solution. 
Bone morphogenic protein-2 (BMP-2) was incorporated into PLGA scaffolds using this 
method. [128, 129] The major disadvantage of this approach is the uncontrolled release 
profile and a very short release duration. 
        Blending electrospinning approach mixes growth factor within the polymer solution 
and electrospinning the mixed solution into a hybrid scaffold with growth factors 
localized within the fibers of the scaffold. This approach is also called " emulsion 
electrospinning" when growth factor is emulsified into polymer solution by ultra-
sonication or homogenization. [136-139]Compared to physical adsorption, blend 
electrospinning approach usually results in a more sustained growth factor release from 
scaffold which can last over several weeks. A typical growth factor release profile from 
blend electrospun scaffold consists of an initial burst release followed a sustained release. 
[128, 140] BMP-2 and epidermal growth factor (EGF) were incorporated into scaffold 
using this approach. [129, 130, 132] The major disadvantage of this approach is the loss 
of bioactivity of the incorporated growth factors due to their conformational changes in 
the organic solution environment or under harsh mixing conditions. [141] Several 
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strategies have been applied to address this issue including addition of hydrophilic 
polymers such as poly(ethylene glyco) (PEG) in the aqueous growth factor solution to 
improve protein stability [130, 142]and addition of hydrophilic hydroxyapatite (HAP) 
particle to attach growth factors, reducing the damage of harsh electrospinning process. 
[129] 
        Coaxial electrospinning, also called co-electrospinning, can produce growth factor 
containing composite nano-fibers with core-shell structures by coaxially and 
simultaneously electrospinning a growth factor solution and a polymer solution through 
different feeding capillary channels in one needle. [143, 144] The growth factor release 
profile from coaxial electrospun scaffolds is similar to that from blend electrospun 
scaffolds, consisting of two stages. [131] However, the burst release is significantly lower 
and the release duration is prolonged, [145, 146]because the growth factors are mainly 
incorporated and distributed in the core part. The polymer shell provides a barrier 
membrane that controls the protein diffusion rate. [145]Introduction of porogens in the 
polymer shell is able to further adjust the growth factor release profile from the coaxial 
electrospun scaffold. [147]Platelet-derived growth factor-b (PDGF-bb) [133, 134], nerve 
growth factor (NGF) [148] and fibroblast growth factor (FGF) [131] have been 
encapsulated in coaxially electrospun scaffolds. 
        Covalent immobilization introduces chemical bond to immobilize growth factors on 
the electrospun fiber surface. Epidermal growth factor (EGF) was delivered from 
electrospun scaffold using this strategy. [135] Due to its technical complexity and 
possible loss of scaffold uniformity, it has not been a routine approach to delivery growth 
factors from electrospun scaffolds.         
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        Besides these four major approaches discussed above, microsphere(MS)/nanosphere 
(NS) encapsulation were also explored to deliver growth factor from electrospun 
scaffolds. However, this method is uncommon due to technique difficulty associated with 
electrospun scaffold's limited pore size. Electrosprying and electrospinning techniques 
were combined to incorporate insulin-like growth factor-containing MS into an 
electrospun PLGA nanofibrous scaffold. [149] In another case, a poly(caprolactone) 
(PCL) jet and a poly(ethylene oxide) (PEO) jet with pre-fabricated MS were both 
electrospun onto a common mandrel and the MS were entrapped within the PCL scaffold 
after PEO was removed. [150] 
 
Growth factor delivery from three dimensional (3-D) porous scaffold 
         Several techniques have been applied to incorporate and deliver growth factor from 
three dimensional (3-D) porous scaffolds, including direct encapsulation, passive 
absorption, coating and microsphere (MS)/nanosphere (NS) encapsulation.   
         Osteotropic factors were mixed with PLGA emulsion and directly encapsulated 
inside PLGA porous scaffold walls during an emulsion freeze-drying scaffold fabrication 
process. [151] Bone morphogenetic protein-2 released from such scaffold enhanced 
ectopic bone formation in rats. [152] While it combined the scaffold fabrication and 
growth factor incorporation into one single step, however, the scaffolds' structure, 
mechanical properties are altered and growth factor release rate depends on scaffold bulk 
degradation rates which may not be ideal for some tissue engineering applications. In an 
alternative method, pre-fabricated porous scaffold  was immersed in a protein solution to 
passively absorb the proteins on the surface of scaffold. [153] However, the release 
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profile of growth factor from a scaffold is not controlled, resulting in a very short release 
period. The growth factors are not protected, resulting in their denaturation and failure to 
achieve the desired biological effects.  [153] Polymer emulsion coating method is also 
used to coat growth factors on the surface of pre-fabricated porous scaffold. The 
bioactivity of the growth factor is protected and the release time period is extended by the 
introduction of a protective polymer layer. However, the porous structure of the scaffold 
is altered by the coating process. [154, 155] 
        In order to overcome these shortcomings associated with the above discussed 
methods of growth factor incorporation into scaffolds, our lab developed techniques to 
encapsulate growth factors into polymer microsphere (MS)/nanosphere (NS) and then to 
immobilize these spheres onto the nanofibrous pore surface of pre-fabricated 
scaffolds.[156, 157]  The typical procedures contain two steps: First, an aqueous growth 
factor solution is mixed with a PLGA polymer solution to encapsulate growth factor 
domains into PLGA spheres using a water-in-oil-in-water double emulsion process. [158, 
159] The sphere size ranges from nanometers to micrometer depending on the emulsion 
process parameters such as surfactant concentration and emulsion strength applied. [160] 
Then these obtained growth factor-containing PLGA MS/NS are immobilized onto the 
inner nanofibrous pore surface of a pre-fabricated scaffold using a post-seeding 
method.[156, 157] This novel MS/NS encapsulation method offers several advantages 
over other scaffold growth factor delivery systems. First, the scaffold fabrication process 
is separated from the growth factor incorporation process. Thus, the macro-porous 
architecture, the mechanical and degradation properties of the scaffold are not altered.  
The release of growth factors and the degradation of the scaffold can be individually 
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optimized. Second, polymeric MS/NS have been widely applied to encapsulate bioactive 
molecules and their ability to protect the encapsulated bioactive molecules from 
denaturation and degradation has been demonstrated. [161, 162] Third, the release of 
growth factors released from the scaffolds are in a temporally controlled fashion, which is 
primarily determined by the chemical and degradation properties of MS/NS polymer 
formulation. The release of the encapsulated proteins takes two phases, with the first 
phase mainly controlled by diffusion and the second phase mainly controlled by polymer 
degradation. Various release duration from several days to months can be easily achieved 
by adjusting polymer formulations such as PLGA copolymer LA/GA ratio or/and the 
molecular weight of the copolymer, showed in Fig.2.6. Fourth, the immobilization of 
MS/NS on porous NF scaffolds can reduce the burst release of growth factors and 
prolong the release duration. [156]  
 
Summary 
    Although nanostructured biomaterials are relatively new scientific and engineering 
field, they have developed rapidly over recent years. Nanofibrous biomaterials, 
nanocomposite biomaterials, micro- and nanospheres discussed herein and have had 
significant impacts on the tissue engineering and regenerative medicine fields. In 
literature, electrospinning and phase separation techniques have been used individually to 
fabricate nanofibrous scaffolds. In this thesis, a new nanofibrous scaffold will be 
fabricated using the combination of these two techniques to mimic more complex tissue 
structure, which will be discussed in Chapter 6. In literature, single growth factor has 
been released from nanofibrous PLLA nanofibrous scaffold. In this thesis, release of 
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small molecule drugs from nanofibrous scaffold will be discussed in Chapter 3 and dual 
release of growth factors from nanofibrous scaffold will be discussed in Chapter5.
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Fig.2.1. SEM micrographs of a PLLA fibrous matrix SEM micrographs of a PLLA 
fibrous matrix prepared from 2.5% (wt/v) PLLA/THF solution at a gelation temperature 
of 8°C: (a) ×500; (b) ×20K. Ma and Zhang, J. Biomed.Mater.Res.46,66(1999). © 1999, 
John Wiley & Sons. 
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Fig.2.2. Fabrication process of sugar sphere template leaching and thermally induced 
phase separation technique, shown by SEM micrographs: (e, f) 3D macroporous and 
nanofibrous scaffold at low (×50) and high (×10,000) magnifications. Wei and Ma, J. 
Biomed.Mater.Res.78,307(2006). © 2006, John Wiley & Sons. 
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Fig.2.3. Scaffolds created from 3-D reconstructions of CT-scans or histological sections. 
(a) Human ear reconstruction from histological sections and (b) the resulting NF scaffold 
(scale bar; 10 mm), (c) human mandible reconstruction from CT-scans. Purple segment 
shows the reversed image of the bone fragment to be engineered, (d) resulting NFscaffold 
of the mandible segment (scale bar; 10 mm), (e) SEM micrographs of the interconnected 
spherical pores within the mandible segment (scale bar; 500 mm), and (f) the NF pore 
morphology of a spherical pore (scale bar; 5 mm). Chen,Smith and Ma, Biomaterials 
27,3976(2006). © 2006,Elsevier Ltd. 
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Fig.2.4. SEM micrographs of NHAP/PLLA (30:70) scaffolds fabricated using 
dioxane/water mixture solvents. (d,f) Dioxane:water=87:13, ×45, ×10000. Guo, Ma, 
Biomaterials 25,4749(2004). © 2006, Elsevier Ltd. 
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Fig. 2.5. SEM micrographs of nanofibrous PLLA/nHAP (90:10) composite scaffolds 
incubated in ×1.5 SBF for varying times. (a, b) 4 days [(b) is a portion of (a) at a higher 
magnification in which the newly formed bone-like apatite is colored green]; (c, d) 30 
days. Guo, Ma, J.Biomed Mater Res 78A,306(2006). © 2006,Wiley Periodicals, Ltd. 
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Fig. 2.6. In vitro release kinetics of rhBMP-7 from nanospheres immobilized on nano-
fibrous scaffolds in 10 mM PBS. Three distinct rhBMP-7 release profiles were achieved 
with NS composed of different PLGA formulations. (PLGA50-6.5K: LA/GA ratio: 50/50, 
Mw:6.5K; PLGA50-64K: LA/GA ratio: 50/50, Mw:64K; PLGA75-113K; LA/GA 
ratio:75/25, Mw:113K) [157] Reproduced with permission from Elsevier. 
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Chapter 3 
Novel antibacterial nanofibrous PLLA scaffold 
 
Introduction 
        Chronic inflammation diseases caused by bacterial infection such as periodontitis 
and septic arthritis remain common in the United States and throughout the world. For 
example, approximately half of the adult population in the US suffers chronic 
periodontitis. This disease is initiated by pathogenic infection on the tooth’s surface as a 
microbial biofilm which gradually leads to the destruction of the periodontal tissue, 
supporting alveolar bone, and eventually leading to tooth loss. [1] In the treatment of 
periodontitis, antibiotics such as tetracycline (TCL) and metronidazole have been 
frequently used.  
        Doxycycline (DOXY) is a well known broad-spectrum antibiotic, which is effective 
against both gram-positive and gram-negative bacteria, protozoa, and various anaerobes. 
[2] As a tetracycline analogue, it can work as a bacteriostatic which is capable of 
inhibiting the bacterial protein synthesis at the ribosomal sites. [3] Compared to TCL, 
DOXY has certain advantages such as a longer half-life, higher lipid solubility, and 
greater oral absorption. [4] It also shows strong inhibition of matrix metalloproteinases 
(MMPs) both in vitro and in clinical studies. [5-9] After being introduced to the clinical 
area in 1967[10], DOXY has been frequently used in treating destructive periodontal 
diseases such as juvenile periodontitis and acute periodontal abscesses. It has been used 
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against periodontal infection and enhancing bone regeneration after periodontal disease. 
[11] It has also been used to prevent bacterial infection related to septic arthritis. [10, 12] 
However, there are some concerns over possible side effects such as gastro-intestinal 
disturbance, esophageal erosion, and photosensitivity when administrated orally [4, 13-
17]. Therefore, in order to reach the site of infection in deep tissues with an effective drug 
concentration and to cirmvent the systemic side effects, controlled localized delivery of 
DOXY is desired. 
        Many attempts have been made in the area of controlled delivery of the DOXY/TCL 
family and certain progress has been achieved. Drug encapsulation methods such as 
mixing, emulsification, and electrospinning have been used. Delivery systems in the 
forms of particles, stripes, hollow fibers, gels, and cements have been fabricated. [18-
24]However, most systems release all the encapsulated DOXY from hours up to 2 weeks. 
While a high initial burst release is acceptable for a highly hydrophilic antibiotic such as 
DOXY/TCL in order to immediately achieve effective concentration, it is also necessary 
to attain a long term sustained release to fight against chronic infection and avoid 
repeated local drug administration. How to achieve both reduced initial burst and 
extended release duration remains a challenge.  
        Controlled release of proteins has been widely investigated. [25-30] Our laboratory 
has previously developed a novel growth factor delivery system. The growth factors were 
encapsulated into PLGA nanospheres and the nanospheres were then incorporated into 
three dimensional (3-D) macro-porous and nano-fibrous PLLA scaffolds. [31-33] The 
function of this delivery system is two fold: First, it serves as an osteoconductive scaffold. 
With its suitable pore structure and nano-fibrous structure similar to collagen, it improves 
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cell attachment, proliferation and differentiation. [34, 35] Second, it stimulates 
vascularization or bone formation by localized controlled delivery of a bioactive 
angiogenic or osteogenic growth factor. [31, 32] In this paper, we incorporated DOXY-
containing PLGA nanospheres into the nano-fibrous scaffolds to evaluate their anti-
bacterial capacity. The combination of the osteoconductive properties of the macro-
porous and the nano-fibrous scaffold with its ability to release antibiotics could be a good 
candidate for local treatment of oral and periodontal diseases. 
 
Materials and methods 
Materials 
        Doxycycline hyclate, D-fructose, mineral oil, and sorbitanmonooleate (span 80) 
were obtained from the Sigma-Aldrich Chemical Company (St. Louis, MO). PLGA 
copolymers with LA/GA ratio of 50:50 (Lakeshore Biomaterials™, PLGA50-6.5K, Mw 
= 6.5 kDa; PLGA50-64K, Mw = 64KDa); PLGA copolymers with a LA/GA ratio of 
75:25 (Lakeshore Biomaterials™, PLGA75-113K, Mw = 113 kDa) and the PLGA 
copolymers with a LA/GA ratio of 85:15 (Lakeshore Biomaterials™, PLGA85-142K, 
Mw = 142 kDa) were purchased from SurModics Pharmaceuticals Inc. (Birmingham, 
AL). Poly(L-lactic acid) (PLLA) with inherent viscosity of 1.6 dl/g was purchased from 
Boehringer Ingelheim (Ingelheim, Germany). Poly(acrylic acid) (MW = 5000) and 
poly(vinyl alcohol) (PVA) (88 mol% hydrolyzed, MW = 25,000) were obtained from 
Polysciences Inc. Hexaglyceryl polyricinolate (Hexaglyn PR-15) was provided by the 
Barnet Products Corp (Englewood Cliffs, NJ). Acetonitrile and petroleum ether (BP 60-
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95 °C) were obtained from Acros Organic (Morris Plains, NJ). Dichloromethane (DCM), 
cyclohexane, hexane, tetrahydrofuran (THF) and Fisherbrand regenerated cellulose 
dialysis bags (nominal MWCO 3500) were purchased from Fisher Scientific (Pittsburgh, 
PA). 
 
DOXY containing PLGA nanospheres (NS) and NS-incorporated nano-fibrous 
scaffold (NS-scaffold) preparation 
        Doxycycline-containing PLGA NS were fabricated using a modified water-in-oil-in-
oil (w/o/o) emulsion method [36, 37]. Briefly, 80 mg PLGA was dissolved in 1 ml 
solvent mixture of acetonitrile/DMC (3:2 in volume ratio). 100 µl aqueous solution of 
certain amount of DOXY was added into the above solution and emulsified with a probe 
sonicator at 50 W (Virsonic 100, Gardiner, NY). This primary w/o emulsion was then 
emulsified into 30 ml of mineral oil containing 4% hexaglyceryl polyricinolate under 
sonication at 90 W to form the w/o/o emulsion. The resulting secondary emulsion was 
magnetically stirred at room temperature for 12 h to evaporate the solvents. The spheres 
were collected by centrifugation and washed three times with petroleum ether and freeze 
dried. Four PLGA formulations: PLGA50-6.5K, PLGA50-64K, PLGA75-113K and 
PLGA85-142K were used for the in vitro release study. The macro-porous PLLA nano-
fibrous scaffolds with dimensions of 7.2 mm in diameter and 2 mm in thickness were 
prefabricated by a combination of phase separation and sugar leaching techniques 
previously described [33]. The PLGA NS were incorporated onto PLLA scaffolds using a 
post seeding method {Wei, 2006 #6; Wei, 2007 #5}. Briefly, PLGA NS were dispersed 
in hexane with 0.1% span 80 and were seeded onto NS-scaffolds drop wise. Then, the 
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scaffolds were subject to vapor of a mixed solvent of hexane/THF (volume ratio 9:1) for 
30 min. The scaffolds were vacuum-dried for 3 days to remove the solvent. 
 
Characterization of PLGA NS and NS-scaffolds 
        The morphology and size of the nanospheres and the scaffolds (before and after NS 
incorporation) were examined using scanning electron microscopy (Philips XL30 FEG 
SEM). The nanospheres were dispersed in hexane and deposited onto a metal stub. SEM 
figures of these spheres were taken after gold coating. Average diameters of all type of 
PLGA spheres studied were calculated based on the sizes measured from the SEM 
images using ImageJ software (National Institutes of Health). The sizes of PLGA50-6.5K 
and PLGA85-142K spheres were also measured by dynamic light scattering (DLS) in an 
aqueous solution for comparison (Delsa Nano C Particle Size Analyzer, Beckman Coulter 
Inc). The drug content and encapsulation efficiency were determined by UV 
spectrophotometric analysis. Briefly, 10 mg DOXY-encapsulated nanospheres (or one 
NS-scaffold) were dissolved in dichloromethane. Then, 10 ml PBS was added to extract 
DOXY. The extraction process was repeated several times. The solution was filtered 
through a 0.45 µm filter to remove polymer debris and then the DOXY concentration was 
measured using a UV spectrophotometer (Hitachi U2910) at the λmax value of 274 nm. 
PBS was used as the control. 
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In vitro drug release studies 
        The release profiles of DOXY loaded NS or NS-scaffolds with four PLGA 
formulations were investigated in PBS (0.1 M). 10 mg NS were suspended in 1 ml PBS 
and placed within a dialysis bag. The dialysis bag was kept in a glass flask containing 20 
ml PBS. One NS-scaffold was suspended in 1 ml PBS in a glass vial. Both the glass vial 
and the glass flask were covered in aluminum foil and shaken at 50 rpm at 37 °C. At 
designated time points (1, 3, 5, 7, 10, 14, 21, 28, 35, 42 days), the release medium was 
withdrawn and replaced with pre-warmed fresh PBS. The released amounts of DOXY 
were analyzed using a UV spectrophotometer at the λmax value of 274 nm [22]. For 
DOXY release through the dialysis bag from NS alone, PBS was used as the control. For 
DOXY release from NS-incorporated scaffolds, blank PLGA NS (without DOXY) were 
immobilized onto the scaffolds and were used as the controls. The absorbance values of 
the controls were subtracted from those of the DOXY containing samples. 
 
In vitro antibacterial activity of NS-scaffold 
        The antibacterial assay was performed as previously described [38]. The overnight 
incubated bacteria solution (S. aureus and E. coli) was diluted with sterile Müeller–
Hinton Broth and reached an absorbance value between 0.1 and 0.2 at 625 nm (equivalent 
to 0.5 McFarland standard). First, the bacterial clone formation assay was performed 
using the Müeller–Hinton agar (1.5%) plate. The scaffolds with or without DOXY 
nanospheres were placed in the center of the melting agar just before solidification. The 
DOXY was allowed to diffuse from the scaffold into the agar for 4 h before 100 µL 
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inoculum was spread over the agar plate. The plates were incubated at 37 °C for 5 days. 
The bacterial growth on plates was visualized directly on the plate. Second, the released 
drug solutions, collected from different scaffold groups at different time points, were 
mixed with 2X Müeller–Hinton Broth and overnight inoculum (the bacterial final 
absorbance value was around 0.1 at 625 nm). All tested solutions were incubated at 37 °C 
on a shaker (50 rpm). The absorbance at 625 nm was monitored after 12 h of incubation. 
The percentage of bacterial inhibition was calculated using the following equation. 
Bacterial inhibition (%) = abs(Ic − Is)/(Ic) × 100, where Ic and Is are the absorbances of the 
control bacterial solution without drug and bacterial solutions with released drug 
respectively at 625 nm after 12 h [38]. 
 
Results 
PLGA nanospheres loaded PLLA nano-fibrous scaffolds 
        PLGA NS prepared from a modified w/o/o double emulsion process were of smooth 
surface (Figure 3.1A). The combination of the phase separation and sugar sphere 
templating techniques allowed the formation of PLLA scaffolds with a high porosity 
(98%), multi-level pore structures and nano-fibrous architecture of the pore walls. The 
scaffolds prepared for this study have regular spherical macro-pores 250–425 µm in 
diameter with well interconnected inter-pore openings of ∼ 100 µm (Figure 3.1B). The 
scaffold walls are entirely made of the PLLA nanofibers with the diameter range of 50–
500 nm (Figure 3.1C), which is similar in size to native collagen fibers. Figure 3.1D and 
51 
 
Figure 3.1E show a cross section of the scaffolds after the DOXY loaded NS 
incorporation, and the pore wall surface at a higher magnification. From SEM 
observation, it is clear that the macro-pores and inter-pore opening structure of the 
scaffolds were well preserved and the nanospheres were uniformly distributed throughout 
the nano-fibrous pore walls. 
        Four different PLGA NS formulations were examined for encapsulation efficiency 
and release behavior. Two of the copolymers had the same LA/GA ratio of 50/50 but 
different molecular weights, PLGA50-6.5K (Mw: 6.5 K) and PLGA50-64K (Mw: 64 K). 
The other two had different LA/GA ratios: PLGA75-113K with a LA/GA ratio of 75/25 
(Mw: 113 K) and PLGA85-142K with a LA/GA ratio of 85/15 (Mw:142 K). The effects 
of processing parameters such as polymer concentration, volume ratio of drug solution to 
inner oil phase (w/o1), volume ratio of inner oil to outer oil phase (o1/o2), the addition of 
PAA on the DOXY encapsulation efficiency (EE) of PLGA85-142K NS are presented in 
Table 3.1. It was observed that the EE of DOXY increased with an increase in the 
polymer concentration from 3% to 8%, no significant difference between 8% and 10%. 
With the increase of aqueous drug volume, the encapsulation efficiency decreased. The 
higher polymer concentration may entrap the aqueous DOXY droplets more efficiently 
(higher EE), while the greater aqueous DOXY volume destabilizes the emulsion (lower 
EE). The increase in the volume ratio of outer oil phase to inner oil phase did not change 
EE significantly. It was found that the addition of poly(acrylic acid) (PAA) as a co-
encapsulation factor did not have significant effect on the EE of the DOXY. 
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        The diameter and the DOXY encapsulation efficiency of NS of four PLGA 
formulations with the same other processing parameters are listed in Table 3.2. Based on 
SEM measurement, the average diameter of the spheres increased with the increase of 
LA/GA ratio and/or PLGA molecular weight, with PLGA50-6.5K NS had the smallest 
diameter of 300 nm and PLGA85-142K NS had the largest diameter of 730 nm. Based on 
DLS measurement, the diameter of PLGA50-6.5K NS and PLGA85-142K NS was 400 
nm and 890 nm respectively in aqueous solution, possibly due to some degree of swelling 
or/and certain discrepancy between the two different methods. The changes in size and 
shape of similar PLGA spheres in aqueous solution over long-term culture were reported 
previously by our lab [39] and others [36]. Such PLGA spheres swelled first and then 
deformed from their original spherical shape into irregular shape with a rough surface 
texture over time. Eventually, they collapsed and disintegrated as the degradation 
continued [39]. EE of DOXY was not changed significantly among different PLGA NS 
formulations. The larger diameter of PLGA85-142K NS was possibly resulted from the 
higher viscosity of the DOXY/PLGA85-142K polymer emulsion compared to those of 
other polymers (Table 3.2). 
 
In vitro DOXY release kinetics 
        In vitro release profiles of DOXY from PLGA NS with four PLGA formulations 
were displayed in Figure 3.2A and release profiles of DOXY from NS-scaffolds were 
shown in Figure 3.2B. Compared to release profiles of DOXY from PLGA NS alone, the 
release from the scaffolds showed a similar release pattern with decreased initial burst 
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release and prolonged release period. In general, the DOXY release profiles of NS-
scaffolds showed two phases: an initial burst release within the first day followed by a 
slow and sustained release over time. There were also significant differences in both the 
burst release rate and sustained release rate of different PLGA formulations. Both 
PLGA50-6.5K NS-scaffold and PLGA50-64K NS-scaffold released approximately 70% 
of DOXY within the first day and 95% of DOXY within 2 weeks, while the PLGA75-
113K NS-scaffold (with a higher LA/GA ratio and higher molecular weight) had a lower 
burst release (50%) in the first day and a slower sustained release of DOXY (85% within 
2 weeks, 95% within 6 weeks). The PLGA85-142K NS-scaffold (with the highest 
LA/GA ratio and the highest molecular weight) had the lowest burst release (25%) in the 
first day and kept a continuous slow release for longer than 6 weeks (80% within 6 
weeks). This two-phase release profile of PLGA nanospheres, characterized by an initial 
burst release followed by a sustained slow release, indicated that DOXY was dispersed in 
a polymeric matrix inside the PLGA nanospheres [40] and [41]. The initial burst release 
was reduced with the increase of the PLGA LA/GA ratio and the PLGA molecular 
weight. PLGA85-142K NS-scaffolds with the lowest burst release and the longest release 
period was selected for in vitro antibacterial test. 
 
In vitro antibacterial effect of DOXY NS-scaffolds 
        The antibacterial activity of the released DOXY was investigated using bacteria 
inhibition experiments. S. aureus and E. coli were used in the current study since they 
represent the most common Gram-positive and Gram-negative bacteria in the human 
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body. The growth of S. aureus and E. coli bacteria can be visualized directly from the 
plate to assess the antibacterial function of all scaffold groups (shown in Figure 3.3). It 
was observed that the agar plates with the BSA scaffolds were totally covered with S. 
aureus or E. coli after 5 days of incubation. In contrast, the growth of S. aureus and E. 
coli were both inhibited at regions around the DOXY adsorbed scaffolds and DOXY NS-
scaffolds. The bacteria inhibited areas were much larger on the plates with the DOXY 
NS-scaffolds than DOXY adsorbed scaffolds. 
        The data from the long-term liquid bacterial culture (S. aureus data shown in Figure 
3.4 and E. coli data shown in Figure 3.5) demonstrated that the antibacterial activity of 
DOXY lasted for more than 6 weeks in the NS controlled release group (showed 70% 
inhibition for S. aureus and 40% inhibition for E. coli at Day 42), while that of the 
adsorbed DOXY decreased rapidly after 14 days (showed 18% inhibition for S. aureus 
and 9% inhibition for E. coli at Day 42) and the BSA scaffold had no antibacterial effect 
even from the very beginning (showed less than 20% inhibition for S. aureus and less 
than 10% inhibition for E. coli). The antibacterial activity of the scaffold measured over 
time was the measurement of the overall antibacterial capacity of the scaffold, including 
the reduced DOXY amount released at a later time and possibly also some biological 
activity loss over time. These results indicated that the encapsulation of DOXY in the 
nanospheres not only can control the DOXY release rate and prolong its release duration 
but also retain its antibacterial activity. 
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Discussion 
        The main objectives of this work were to fabricate the DOXY loaded NS with good 
encapsulation efficiency, to incorporate the NS onto a nano-fibrous scaffold, to release 
DOXY in a controlled manner, and to retain the antibacterial activity. In previous 
publications from our lab, novel nano-fibrous scaffolds capable of delivering growth 
factors were successfully developed [31] and [32]. While water-in-oil-in-water (w/o/w) 
double emulsion method can be readily used to entrap proteins into nanospheres, it is 
difficult to entrap very hydrophilic small molecules such as doxycycline into NS with an 
acceptable encapsulation efficiency (less than 5% showed in Table 3.3) since the high 
solubility of the drug in the external phase and its small size makes it easy for the 
majority of the drug to diffuse to the external phase during the emulsion and solvent 
evaporation process and results in very low encapsulation efficiency [41]. Some 
researchers made modifications to w/o/w method [22] or used other encapsulation 
method [20] to achieve a higher DOXY encapsulation efficiency. However, the EE 
increase was limited and the size of the spheres obtained became much larger, usually in 
the range of 100 µm [22]. The DOXY loaded spheres with this size may be used alone for 
antibacterial treatment, but they are too large to be incorporated into the nano-fibrous 
scaffolds [33]. To overcome these limitations, a modified w/o/o emulsion and solvent 
evaporation method was successfully adopted to encapsulate DOXY into spheres. By 
changing the external continuous phase from water to an organic solvent mixture, the 
diffusion of the drug was reduced due to the decreased solubility of the drug in the 
external phase, and the encapsulation efficiency was greatly improved. It was also 
discovered that the release profile of DOXY from the PLGA NS-scaffolds was mainly 
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determined by the release from NS which can be adjusted by tailoring the chemical 
composition and molecular weight of the PLGA copolymers. The PLGA85 NS-scaffolds 
with the highest molecular weight and highest LA/GA had the lowest initial burst release 
(25%) and longest release duration of DOXY (longer than 6 weeks). This trend is 
consistent with our lab's previous publications on the release profiles of growth factors 
from NS-scaffolds [31] and [32]. The difference in release profiles of PLGA NS-scaffold 
was possibly resulted from both the difference in the NS diameter and PLGA degradation 
rate. PLGA85-142K NS with the largest NS diameter had the smallest specific surface 
area and the longest average travel distance for the encapsulated DOXY to diffuse out of 
the spheres, resulting in the lowest burst release during the earlier release stage. It is also 
possible that the highest viscosity of PLGA85 polymer solution also reduced the 
diffusion of DOXY to the outer oil phase during the emulsion and solvent evaporation 
process so that the least amount of the drug was simply absorbed on or near the NS 
surface, resulting in a reduced initial burst release. PLGA85-142K NS also had the 
slowest degradation rate due to the highest molecular weight and LA/GA ratio, which 
contributed to the slower release rate of DOXY. It was also discovered that incorporating 
DOXY loaded PLGA NS into PLLA nano-fibrous scaffold effectively reduced burst 
release and slowed down the DOXY release rate. The reduced burst release of DOXY 
from nano-fibrous scaffold may have resulted from the adsorption and desorption of 
DOXY on the nanofibers before diffusing out of the scaffolds due to the very high 
surface area (100 m2/g) of the nano-fibrous scaffolds. 
        The antimicrobial experiment demonstrated the biological function of the DOXY 
released from PLGA NS-scaffolds for a long duration (6 weeks), which is a great 
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improvement for the long-term treatment of dental, periodontal and bone infection or 
MMP-inhibition since the commercially available DOXY releasing gels typically release 
all DOXY within 2 weeks [42]. These novel DOXY NS-incorporated nano-fibrous 
scaffolds were intended for tissue engineering applications where microbial infection 
may be involved. While the macro-porous and nano-fibrous scaffolds may promote the 
tissue regeneration, the DOXY NS in the scaffolds may also protect the tissue from 
microbial invasion. Since DOXY is also an inhibitor of multiple MMPs such as MMP-8, 
-9 and -13, DOXY NS-scaffold may also be able to protect engineered bone from MMP 
destruction in situations with chronic inflammation in diseases such as periodontitis and 
rheumatoid arthristis [43]. 
        The 3-D NS-scaffolds developed in this work have shown the capability of 
controlled delivery of DOXY and inhibition of bacterial growth for a prolonged period. 
This success has demonstrated the scaffolds to be capable of controlled delivering small 
hydrophilic drug molecules as well as large proteins. With the versatile delivery 
capability and macro-porous and nano-fibrous structure, the scaffolds may allow for the 
implementation of more comprehensive strategies in tissue engineering. 
Conclusion 
        Results of in vitro release and antibacterial experiments suggest that the developed 
drug-containing nano-fibrous scaffolds are capable of effectively delivering doxycycline 
in a controlled fashion with prolonged duration. These biodegradable PLLA scaffolds 
have well interconnected macro-porous and nano-fibrous structure and can inhibit 
common bacterial growth for more than 6 weeks with the incorporation of DOXY 
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containing PLGA NS. Release kinetics from the scaffolds was found to be determined by 
PLGA formulation. The incorporation of the NS into scaffolds reduced the burst release. 
PLGA85-142K NS-scaffold has the lowest initial burst release and the longest release 
period compared to other formulations investigated. Taken together with earlier studies, 
the NS-scaffold system can be used as a delivery system for both large proteins and small 
drug molecules for various complex tissue engineering applications. 
 
59 
 
 
Fig. 3.1 Characterization of PLGA85-142 K nanospheres (NS) and PLLA nano-fibrous 
scaffold (NS-scaffold) before and after nanospheres incorporation. (A) SEM view of 
DOXY containing PLGA85-142 K NS; (B, C) SEM views of the PLLA scaffold before 
NS incorporation at 100× and 10,000× magnifications respectively; and (D, E) SEM 
views of PLLA scaffold after NS incorporation at 100× and 10,000× magnifications 
respectively. 
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Fig. 3.2 In vitro release kinetics of DOXY from NS (A) and from NS-incorporated nano-
fibrous PLLA scaffolds (B): in 10 mM PBS with DOXY loading of 100 µg/scaffold. 
Each data point represents a mean ± standard deviation (n = 3). 
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Fig. 3.3 Agar petri dish cultivated with S. aureus (upper) and E. coli (lower) with scaffold 
samples in the center after 5 days of incubation. Scaffolds on the left side were seeded 
with BSA containing NS. Scaffolds in the center absorbed 100 µg DOXY. Scaffolds on 
the right side were seeded with NS containing 100 µg DOXY. 
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Fig. 3.4 Long-term S. aureus growth inhibition test for release solution from three groups 
of scaffolds. Each data point represents a mean ± standard deviation (n = 3). 
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Fig. 3.5 Long-term E. coli growth inhibition test for release solution from three groups of 
scaffolds. Each data point represents a mean ± standard deviation (n = 3). 
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Table 3.1 Effects of various processing parameter on encapsulation efficiency of DOXY 
in PLGA85-142K nanospheres. Each EE data point represents a mean ± standard 
deviation (n = 3). Note: w: water phase; o1: inner oil phase (PLGA solution); and o2: 
outer oil phase (mineral oil solution). 
PLGA85-142K 
concentration 
w/o1 PAA 
concentration 
EE (%) 
3% 1:10 0 13.3+5.2% 
5% 1:10 0 15.3+4.1% 
8% 1:10 0 25.3+3.0% 
10% 1:10 0 25.9+3.9% 
8% 1:4 0 8.6+2.1% 
8% 1:5 0 10.8+3.2% 
8% 1:20 0 26.4+3.5% 
8% 1:10 2% 24.4+3.3% 
8% 1:10 4% 23.5+4.5% 
8% 1:10 8% 23.1+5.6% 
8% 1:10 16% 25.7+3.1% 
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Table 3.2 Effects of PLGA composition on sphere diameter with the same other 
processing parameters (8% polymer concentration, 4% PR-15, 1:10 w/o1, and 1:30 o1/o2). 
Each data point represents a mean ± standard deviation. Sphere diameters were measured 
using SEM. 
Polymer LA/GA ratio Mw (kDa) EE (%) Sphere diameter (nm) 
PLGA50-6.5K 50/50 6.5 26.1+4.8 300+110 
PLGA50-64K 50/50 64 24.4+3.5 520+150 
PLGA75-113K 75/25 113 23.1+4.4 570+130 
PLGA85-142 85/15 142 25.3+3.0 730+160 
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Table 3.3 Encapsulation efficiencies (10% polymer concentration, 1% PVA, w1/o = 1:10, 
o/w2 = 1:30). Each data point represents a mean ± standard deviation. Note: w1: aqueous 
drug solution, o: PLGA solution, and w2: aqueous PVA solution. 
 
Polymer LA/GA ratio Mw (kDa) EE (%) Sphere diameter (nm) 
PLGA50-6.5K 50/50 6.5 3.2+1.8 280+70 
PLGA50-64K 50/50 64 2.7+0.5 320+100 
PLGA75-113K 75/25 113 3.1+1.4 370+90 
PLGA85-142 85/15 142 2.3+1.0 410+120 
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Chapter 4 
Nano-fibrous scaffold for controlled release of Recombinant human basic fibroblast 
growth factor 
 
Introduction 
      To address the conflict between the increasing need for tissue and organ 
transplantation and the donor tissue shortage, tissue engineering has been rapidly 
developing. One of the most common approaches in tissue engineering is to seed 
functional cells of interest into three dimensional (3-D) polymeric scaffolds and then 
either culture the tissue constructs in vitro or implant them [1, 2]. One major factor of 
determining the success of many implanted tissue constructs is whether they can 
vascularize rapidly. A lack of blood flow within a tissue may cause ischemia or delayed 
wound healing. [3-5] Inadequate vascularization hinders the regeneration of a variety of 
tissues and decreases the long term survival rate of these tissue implants, because 
sufficient supply of oxygen and nutrients is vital for cells’ growth and function. However, 
native angiogenic process triggered by foreign body response to implantation is too slow 
or limited to support mass transport for cells in most thick tissue or cell/scaffold 
constructs. [6-8] Therefore, it is advantageous to incorporate angiogenic strategy in a 
tissue engeineering approach to stimulate rapid blood vessel formation of high local 
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density. 
      Basic fibroblast growth factor (bFGF), a 18-KDa heparin-binding protein, is 
capable of enhancing the proliferation of fibroblasts, smooth muscle cells, hepatocytes 
and endothelial cells.[9-12] bFGF is one of the angiogenic growth factors that have been 
used to stimulate angiogenesis for tissue regeneration in animal studies and clinical trials. 
[13-16] However, injected bFGF in a solution form loses its biological function rapidly 
due to its diffusion away from the application site and degradation in vivo, [17] high or 
repeated doses are usually needed to maintain sufficient therapeutic concentration. To 
avoid such growth factor waste and inconvenient administration mode, a localized 
delivery system to release bFGF in a controlled fashion is highly desired. While simple 
adsorption of growth factors onto a scaffold may help local delivery to certain degree, the 
loading efficiency is low and the release is not in a controlled way. [18] Several other 
attempts have been made to specifically incorporate bFGF into scaffolds such as gelatin 
hydrogels, alginate beads, collagen sponges, [19-22] but they suffered the drawback of 
short release duration (less than a week). We take a new approach to immobilize 
bFGF-encapsulated poly(lactide-co-glycolide) (PLGA) nanospheres onto the pore walls 
of scaffolds to achieve controlled release. By varying the protein loading amount, LA/GA 
ratio of PLGA copolymer, and the PLGA molecular weight, the release rate and initial 
burst release of the growth factors can be modulated primarily by the PLGA nanospheres. 
[23, 24] Several growth factors' bioactivity has been well preserved by incorporating 
them in biodegradable microspheres when appropriate formulations are used. [25-27]  
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      Previously, our laboratory successfully fabricated macro-porous nano-fibrous 
PLLA scaffolds with good mechanical properties, [28, 29] which successfully enhanced 
cell attachment, proliferation, and differentiation due to its nano-fibrous structure similar 
to that of collagen[30-33]. We have also successfully encapsulated a few growth factors 
into microspheres or nanospheres and incorporated these spheres into scaffolds to 
achieve controlled release. [27, 34, 35] However, investigation on the effects of growth 
factor release profile and dosage on its in vivo function has not been performed before. In 
this work, basic fibroblast growth factor (bFGF) containing PLGA nanospheres were 
immobilized onto a PLLA nano-fibrous scaffold. The morphology of the scaffolds and 
bFGF-containing PLGA nanospheres was observed. The release profiles of the 
nanospheres, nanosphere incorporated scaffolds, bioactivity of released bFGF, in vivo 
angiogenesis were examined. The effects of bFGF release rate and bFGF incorporation 
dosage on in vivo cell penetration and vascularization were also investigated. 
 
Materials and methods 
Materials 
      bFGF was kindly provided by Shenandoah Biotechnology Inc (Warwick, PA) and 
Akron Biotechnology, LLC (Boca Raton, FL). Radio labeled bFGF (125I-bFGF) was 
purchased from PerkinElmer Life And Analytical Sciences, Inc (Waltham, MA). Bovine 
serum albumin (BSA, Fraction V), sodium heparin (Mw 12,000 KDa) D-fructose, 
mineral oil, and sorbitanmonooleate (span 80) were purchased from Sigma-Aldrich 
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Chemical Company (St. Louis, MO). PLGA copolymers with LA/GA ratio of 50:50 
(Lakeshore BiomaterialsTM, PLGA 50-6.5K, Mw=6.5kDa; PLGA 50-64K, Mw=64KDa) 
and 75:25 (Lakeshore BiomaterialsTM, PLGA 75-113K, Mw=113 kDa) were purchased 
from SurModics Pharmaceuticals Inc. (Birmingham, AL). Poly (L-lactic acid) (PLLA) 
with inherent viscosity of 1.6 dl/g was purchased from Boehringer Ingelheim (Ingelheim, 
Germany). Poly (vinyl alcohol) (PVA) (88 mol% hydrolyzed, Mw= 25,000 KDa) was 
obtained from Polysciences Inc. (Warrington, PA). Dichloromethane (DCM), 
cyclohexane, hexane and tetrahydrofuran (THF) were purchased from Fisher Scientific 
(Pittsburgh, PA).  
 
Preparation of PLGA NS and NS incorporated nano-fibrous scaffold (NS-scaffold) 
      bFGF powder was dissolved in 10 mM PBS with the same amount of heparin as 
bFGF and 50 folds of BSA to form a clear aqueous solution. PLGA nanospheres were 
fabricated to incorporate bFGF (50µg/100mg polymer) using an established double 
emulsion technique as described previously.  [27, 34, 35] Three PLGA formulations: 
PLGA50-6.5K, PLGA50-64K and PLGA75-113K were used for in vitro release study 
and radio-labeled 125I-bFGF was added as a tracer (125I-bFGF: unlabeled bFGF= 1:100). 
bFGF (200µg/100mg polymer) were incorporated into PLGA50-64K NS for in vivo study. 
Blank NS containing only heparin and BSA were prepared as the control. Macro-porous 
nano-fibrous PLLA scaffolds were prepared by a combination of phase separation and 
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sugar leaching techniques as described previously. [29] These disc-shaped scaffolds were 
7.2 mm in diameter and 2 mm in thickness. 
      PLGA50-64K NS was incorporated onto PLLA scaffolds using a post seeding 
method. Briefly, PLGA NS was dispersed in hexane and seeded onto NS-scaffolds drop 
wise. Then the scaffolds were subjected to a vapor of a mixed solvent of hexane/THF 
(volume ratio 9:1). The scaffolds were vacuum-dried for 3 days to remove the solvent. 
The morphology of the nanospheres and the scaffolds before and after nanospheres 
incorporation was examined using scanning electron microscopy (Philips XL30 FEG 
SEM). 
 
In vitro release study 
      In vitro bFGF release profiles from both PLGA NS and PLGA NS incorporated 
PLLA scaffolds were determined by radioactivity detection as follows: One NS-scaffold 
or 10 mg nanospheres were suspended in 1.0 ml phosphate buffered saline (PBS, 10 mM, 
pH=7.4, with 0.1% BSA) at 37 ℃ with orbital shaking at 60 rpm. At the designated time 
points: 1, 3, 5, 7, 10, 14, 21, 28, 35, 42, 49, 56 and 63 days, supernatant was collected and 
replaced with an equal amount of fresh medium. The radioactivity of collected 
supernatant was analyzed by a gamma counter (Gamma 5500, Beckman) and the released 
bFGF amount was calculated. BSA/heparin containing NS and NS-scaffolds were used as 
controls. 
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Subcutaneous implantation 
      For implantation, male C57BL/6 mice with an age range of 6-8 weeks (Charles 
River Laboratories) were used in the study. The animal procedures were performed 
according to the protocol approved by the University of Michigan Committee of Use and 
Care of Laboratory Animals. Surgery was performed under general inhalation anesthesia 
with isofluorane as previously described [27]. The back of the animals was shaved, 
washed and disinfected with povidoneiodine. Two midsagittal incisions were made on the 
dorsa and two subcutaneous pockets were created using blunt dissection. One scaffold 
was implanted subcutaneously into each pocket. After placement of the scaffolds, the 
incisions were closed with staples. The scaffolds were randomly implanted into mice and 
three scaffolds were implanted for each experiment group (n=3 animals/group). In order 
to investigate the bioactivity of the released bFGF, three groups of scaffolds were 
implanted: controlled empty nanofibrous scaffold group, nanofibrous scaffold group with 
simple absorption of 3µg bFGF/scaffold and nanofibrous scaffold group with 
PLGA50-64K nanospheres containing 3µg bFGF/scaffold. At the end of each 
implantation period (4, 7 and 14 days), the mice were sacrificed and the scaffolds were 
harvested. In order to investigate the effects of bFGF release rate and dosage on bFGF 
biological functions in vivo, seven groups of scaffolds were implanted into mice (n=3 
animals/group).  They are: controlled group, group with PLGA50-6.5K nanospheres 
(3µg bFGF/scaffold), group with PLGA50-64K nanospheres (3µg bFG/scaffold), 
nanofibrous scaffold group with PLGA75-113K nanospheres (3µg bFGF/scaffold), group 
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with PLGA50-6.5K nanospheres (0.3µg bFGF/scaffold), nanofibrous scaffold group with 
PLGA50-6.4K nanospheres (1.5µg bFGF/scaffold) and group with PLGA50-6.5K 
nanospheres (6µg bFGF/scaffold). The mice were sacrificed and the scaffolds were 
harvested after 7 days. 
 
Histological examination 
      The harvested grafts were fixed in 10% neutral buffered formalin, embedded in 
paraffin, and longitudinally cut into 5 mm thick cross sections. Selected sections were 
stained with hematoxylin and eosin to evaluate the nature of tissue neogenesis. Images of 
these specimens were captured using a Nikon Eclipse 50i Microscope (Nikon, Inc., 
Melville, NY) fitted with a Nikon Digital Sight DS U1 Camera (Nikon, Inc, Melville, NY) 
for analysis using Image Pro PlusTM Software (Media Cybernetics, Silver Spring, MD). 
The entire area of the specimen and the area with tissue penetration were measured. The 
remaining slides were used to perform Factor VIII-related antigen/von Willebrand factor 
immunohistochemical staining with an anti-human Factor VIII-related antigen/von 
Willebrand factor rabbit polyclonal antibody (NeoMarkers, Fremont, CA)  or a rabbit 
anti-mouse polyclonal antibody (1:50 dilution) (Abcam, Cambridge, MA). The number 
of positive-stained blood vessels within the scaffolds was measured. 
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Results 
Characterization of bFGF nanospheres and NS scaffolds 
     bFGF was incorporated into PLGA nanospheres using a double emulsion 
technique and three different PLGA formulations (PLGA50-6.5K, PLGA50-64K, 
PLGA75-113K) were used. All nanospheres made from different PLGA formulations 
were in a spherical shapes as shown in Figure 4.1(A). The nanospheres of all PLGA 
formulations have a high encapsulation efficiency of bFGF (68-73%), which was 
determined by radioactivity detection. Based on SEM observation, the average diameter 
of the NS was approximately 500 nm.  
      3-D macro-porous and nano-fibrous PLLA scaffolds were prepared with a high 
porosity of 98%. SEM observation showed (Figure 4.1(b-c)) that the scaffold possessed 
multi-level porous architecture. It had spherical macro-pores of 250-425 µm in diameter, 
inter-pore opening of ~ 100 µm, and nano-fibers of 50-500 nm in diameter within the 
pore wall of the scaffolds. These nano-fibers were similar to type I collagen fibers in size. 
The well interconnected porous structure and the nano-fibrous structure were not only 
important for the cellular activity and tissue penetration, but also efficient for the 
incorporation of the growth factor containing NS. 
      Figure 4.1(d-e) shows the morphology of scaffolds after PLGA50-64K 
nanosphere incorporation. Both the spherical macro-pore and inter-pore opening 
structures of the scaffolds were well preserved after NS incorporation. The nanospheres 
were attached to nano-fibers on the pore walls and distributed throughout the scaffolds. 
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In vitro bFGF release kinetics 
      Cumulative release of bFGF from PLGA NS and PLGA NS incorporated PLLA 
scaffolds was shown in Figure. 4.2 (A) and (B). The release of bFGF from PLGA NS and 
PLGA NS incorporated scaffolds showed similar pattern, while NS-scaffold had a lower 
initial burst release. This observation was in accordance with our lab’s earlier finding on 
BMP-7 release. [27] It was also discovered that release patterns of different PLGA 
formulations were different. bFGF was released from PLGA 50-6.5K NS and 
PLGA50-64K NS scaffold with a 66% and 56% initial burst release respectively. After 
two weeks, 87% and 78% of bFGF were released from these two scaffolds. bFGF release 
from PLGA50-64K NS and PLGA50-64k NS scaffolds showed a multi-phasic pattern. 
The NS and NS scaffolds first rapidly release 46% and 43% during the first two weeks 
with the burst release of 35% and 26% respectively. From week 4, there was a second 
rapid release of near 30% bFGF, which was in accordance with the significant mass loss 
and disintegration of PLGA NS at that time. [27] The bFGF release from both 
PLGA75-113K NS and NS scaffolds were slow with low burst release and sustained 
throughout the whole time period. The initial burst release was decreased significantly 
with an increase in the molecular weight of PLGA and/or LA/GA ratio in the PLGA 
copolymer. This result shows that by adjusting the chemical and degradation property of 
the PLGA nanosphere, bFGF release pattern can be controlled.  
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Controlled release of bFGF stimulated tissue neogenesis and neovascularization 
  Four days after implantation, tissue in-growth into the scaffolds was minimal in 
the BSA and bFGF adsorbed groups, while there was more tissue in-growth into the 
superficial layers of the scaffolds(1-2 layers) in the bFGF NS scaffold release group (Fig. 
4.3A). At Day 7, penetrating tissue occupied half the scaffold space in bFGF NS scaffold 
group, while the tissue penetration was seen only in the superficial regions of the 
scaffolds in the other two groups (Fig. 4.3B). In addition, there was more vascularization 
in the bFGF NS scaffold group than the other two groups. At 14 days, penetrating tissue 
occupied the entire scaffolds in bFGF NS scaffold group. There were still some regions 
without tissue in the bFGF-Adsorbed only scaffold and BSA NS scaffold (Fig. 4.3C). 
Parallel to the histological observations, the histomorphometry measurements of 7 and 14 
days specimens (Fig. 4.4) showed that the tissue penetration percentage (penetration 
tissue area versus the whole area), was significantly higher in the bFGF NS release group 
than in the other two groups. Then, the vascularization within scaffolds was investigated 
for the in vivo effect of released bFGF on blood vessel formation. Factor VIII-related 
antigen/von Willebrand factor immunohistochemical staining was used. Fig. 4.5 indicated 
that at 7 days, vascularization inside the scaffolds was greatest in the bFGF NS release 
group, which is in accordance with the results of measurement of the blood vessel 
number (Fig.4. 6). However, at 3, and 14 days, the blood vessel numbers in the scaffolds 
were not significant different among all groups. 
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Release profile and dosage of bFGF influenced tissue neogenesis and 
neovascularization 
     Seven days after implantation, penetrating tissue occupied almost the entire 
scaffolds in PLGA50-6.5K NS scaffold group (3.0µg bFGF/scaffold), while only 
approximately half of the scaffolds were penetrated by tissue in-growth in PLGA50-64K 
NS scaffold group (3.0µg bFGF/scaffold) and PLGA75-113K NS scaffold group (3.0µg 
bFGF/scaffold). The tissue penetration was seen only in the superficial regions of the 
scaffold in control group without bFGF. (Fig. 4.5A) The histomorphometry 
measurements (Fig. 4.5B) showed that the tissue penetration percentage was significantly 
higher in PLGA50-6.5K NS scaffold group than in the PLGA50-64k NS group and 
PLGA75-113K NS group (Fig. 4.5B). These three scaffolds all have significant higher 
cell penetration than control group. In addition, Fig. 4.6A indicated that at 7 days, 
vascularization inside the scaffolds was greatest in PLGA50-6.5K NS scaffold groups 
which is in accordance with the results of measurement of the blood vessel number(Fig. 
4.6B). According to Fig 4.7. and Fig. 4.8, the tissue penetration and vascularization inside 
scaffolds increased with the increase of bFGF dosage and peaked at 3µg /scaffold dosage, 
while the same PLGA1A NS were used to incorporate bFGF.  
 
Discussion 
  The present study reports for the first time that a 3-D nanofibrous PLLA scaffolds 
with incorporated PLGA NS provides a desired controlled bFGF delivery in vivo and 
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enhances tissue neogenesis and angiogenesis. The biologic function of bFGF depends on 
its release profile from scaffold. With the increase of bFGF release rate, the biologic 
function of bFGF is enhanced. It was also discovered that the biologic function of bFGF 
also depends on bFGF incorporation dosage. It increases with the increase of bFGF 
dosage until an optimal dosage is reached and then it decreases.  
  One of the great challenges in tissue engineering is to provide adequate oxygen 
and nutrients transport to the implants to improve cell penetration and vascular invasion 
to support tissue neogenesis and function. Potent angiogenic agents delivered from the 
tissue engineered scaffolds can enhance this vascularization process. Basic fibroblast 
growth factor, one of the angiogenic agents, has good angiogenic and mitogenic 
properties so that it has been used to stimulate the regeneration of blood vessel [13]and 
other organs. [36, 37] A sustained and controlled drug delivery system is often necessary 
to deliver bioactive bFGF over a prolonged period at the target site to increase the 
therapeutic efficacy of bFGF since bFGF has a short half-life (12 hours in vitro and less 
than three minutes in vivo). [38, 39] Various natural [19, 40-42]and synthetic [43-45] 
polymer delivery systems have been developed for bFGF. The ideal delivery system 
should be able to not only deliver bioactive bFGF in a controlled way but also provide a 
suitable physical and chemical environment for cellular activity and tissue formation. 
  Compared to other delivery systems, this new delivery system offers several 
advantages: First, it provides an excellent environment for cell penetration and 
neogenesis. In the scaffold, PLLA and PLGA are both FDA approved biodegradable and 
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biocompatible synthetic. The scaffolds offer good mechanical properties, high porosity 
(98%), well interconnected macro-pores and inter-pore openings, and a nano-fibrous 
structure. These structures promotes cell attachment, proliferation, differentiation. [30, 32, 
46] Second, bFGF containing PLGA nanospheres were successfully incorporated onto 
nanofibrous scaffolds using a post seeding technique so that the macro and 
microstructures of the scaffolds were well preserved. Third, bFGF released from NS 
immobilized scaffolds were mainly determined by the release pattern of PLGA 
nanospheres and the NS release pattern was controlled by PLGA copolymer’s 
degradation properties. So, it is appropriate to tailor the release kinetics of growth factors 
from NS incorporated scaffold by simply choosing or synthesizing the suitable PLGA 
copolymer for a specific tissue engineering research.  
  Due to the interconnected macro-pores and inter-pore micro openings and the 
nano-fibous structures, after 14 days of implantation, cells and tissues penetrated into all 
scaffold (control, bFGF Absorbed, bFGF NS incorporated) groups (Fig 4.3C). Only 
bFGF NS incorporated scaffolds showed tissue penetration into the entire scaffolds. The 
same trend was observed for tissue in-growth at 7 days after subcutaneous implantation 
(Fig 4.3B). At day 4, only bFGF NS incorporated scaffolds showed significant tissue 
in-growth into the superficial layer. Immunohistochemical staining after 7 days and 
blood vessel number measurement (Fig. 4.4B) also confirmed the advantage of NS 
incorporated NS scaffold over the other two groups in terms of its ability to stimulate 
blood vessel formation throughout the scaffolds. Results from the 4th and 14th day 
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showed no significant difference between groups. It is possible that it was too early for 
the released bFGF to be effective in stimulating blood vessel at Day 4, while at Day 14, 
native angiogenesis process completes, so no significant difference could be observed. 
From these results, it was confirmed that bFGF containing NS scaffolds not only protect 
the bioactivity of the protein against denaturation or degradation, but also release the 
bioactive growth factors in a prolonged and controlled way, while bFGF Absorbed 
scaffolds failed to do so.  
  We also explored the effects of release profile and dosage of bFGF from scaffolds 
on its in vivo biological functions. It was found at 7 days, PLGA50-6.5K NS scaffold 
group showed much higher cell penetration percentage (Fig.4.5) and blood vessel 
formation (Fig. 4.6) than PLGA50-64K and PLGA75-113K NS scaffold groups, while 
the bFGF dosage of all three scaffolds were kept the same at 3µg/scaffold. 
PLGA50-6.5K NS scaffold with the lowest molecular weight and lowest LA/GA ratio 
releases bFGF fastest with a 65% of bFGF released within one week compared to 35% 
and 25% of bFGF released from PLGA50-64K and PLGA75-113K NS scaffold during 
the same time period (Fig 4.2B). The higher amount bFGF released from PLGA50-6.5K 
NS scaffolds stimulated more cell migration into the scaffolds, more cell proliferation 
and caused more blood vessel formation. It was also found at 7 days, bFGF biological 
function was enhanced with the increase of bFGF dosage from 0.3 to 3.0µg/scaffold, 
while all scaffold groups used PLGA50-6.5K NS to incorporate bFGF. (Fig4.7. and Fig 
4.8.) This effect is also caused by the increased concentration of bFGF present inside the 
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scaffolds and surrounding the scaffolds. However, when the dosage of bFGF was 
increased from 3.0 to 6.0µg/scaffold, a decrease in both cell penetration and blood vessel 
formation was observed. The possible explanation for this phenomena is that with the 
excess released bFGF diffused out of the scaffold stimulated cell growth and formed 
much thick connective tissue capsules surrounding scaffolds compared to other groups 
(showed with arrows in Fig. 4.7A). This thick tissue capsules layer prevented both more 
bFGF diffusion out of the scaffolds to recruit cells and cell migration into scaffolds and 
resulted in a decrease in cell penetration percentage and less blood vessel formation in 7 
day time period.  
  Thus, in order to achieve the goal to improve cell penetration and vascular 
invasion into the tissue engineering implants to support neogenesis and function, not only 
angiogenic factors like bFGF needs to be provided with protected bioactivity in a 
prolonged time period, but also they need be provided with a suitable rate and dosage to 
achieve optimal effect. If the dosage is too low, not enough cells will be recruited and 
migrated into scaffold which will result in less tissue penetration and less neo-blood 
vessel formation. On the other hand, if the dosage is applied too high, tissue 
encapsulation will be formed around scaffold to block cell migration which will also 
result in decreased cell penetration and less blood vessel formation. The PLGA NS 
incorporated nano-fibrous PLLA scaffold descried in this study with its cell attachment, 
proliferation, differentiation beneficial macro-porous and nanofibrous 3D structure and 
its easily adjustable controlled release capability of growth factors offers an excellent 
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tool for tissue engineering scientists to achieve this goal. 
 
Conclusion 
  We have developed bFGF containing NS incorporated nano-fibrous scaffold, 
which is capable of releasing bioactive bFGF in a localized and temporally controlled 
fashion with prolonged duration. This NS-scaffold system functioned well to improve 
tissue penetration and blood vessel formation due to both its highly interconnected 
porous structure and its sustained release of bioactive bFGF. The released bFGF 
functions in vivo in a release rate dependent and dosage dependent fashion. This novel 
PLGA NS nano-fibrous scaffold with its 3D refined complex structure and controlled 
bioactive bFGF release capability provides significant potential for multiple tissue 
engineering applications. 
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             Fig 1A 
   
              Fig1B                              Fig 1C 
   
              Fig1D                                Fig 1E                   
Fig.4.1. Characterization of PLGA50-64K Nanospheres (NS) and PLLA nano-fibrous 
scaffold (NS scaffold) before and after NS loading. (A) SEM view of bFGF containing 
PLGA 50-64K NS; (B, C) SEM view of the PLLA scaffold before NS loading at 100 
ⅹ(B) and 10,000 ⅹ(C); (D, E) SEM view of PLLA scaffold after NS loading at 100 
ⅹ(D) and 10,000 ⅹ(E).  
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                                 Fig 2 (A) 
 
 
                          Fig 2(B) 
Fig.4.2 In vitro release kinetics of bFGF from PLGA NS (200 µg bFGF/100 mg polymer) 
(A) and PLGA NS loaded nano-fibrous scaffolds (3 µg bFGF/scaffold) (B) in 10 mM 
PBS. Each data point represents a mean + standard deviation (n=3). 
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Fig 3(A) 
 
 
 
 
 
Fig 3 (B) 
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Fig 3(C) 
 
 
                               
Fig 3(D) 
Fig.4.3. Microscopic observation of the H & E stained tissue sections harvested of three 
scaffolds groups (4 days (A); 7 days (B); 14 days (C) after implantation (Control: no 
bFGF, bFGF Absorbed: 3µg bFGF simple absorption, bFGF NS: 3µg bFGF loaded in 
NS); 4 ⅹ for full cross sections, and 10 for high magnification views. Tissue ⅹ
Penetration percentage calculated from sectioned scaffold groups 4 days, 7days, 14days 
after implantation (D). Each data point represents a mean + standard deviation (n=3). 
*P<0.05.  
 
91 
 
 
Fig 4(A). 
 
 
Fig 4(B). 
 
Fig.4.4 (A) Microscopic observation of the Factor VIII-related antigen/von Willebrand 
factor stained tissue sections harvested of three scaffolds groups 7 days after implantation 
(Control: no bFGF, bFGF Absorbed: 3µg bFGF simple absorption, bFGF NS: 3µg bFGF 
loaded in NS), 10 for high magnification views. (4days and 14days microscopic data ⅹ
not shown) (B) Blood vessel number calculated from sectioned scaffold groups 4 days, 
7days, 14days after implantation. Each data point represents a mean + standard deviation 
(n=3). *P<0.05. 
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Fig 5 (A) 
 
Fig 5(B) 
 
Fig.4.5. (A) Microscopic observation of the H & E stained tissue sections harvested of 
three scaffolds groups 7 days after implantation (3µg bFGF/scaffold); 4 for full cross ⅹ
sections, and 10 for high magnification views. ⅹ (B) Tissue Penetration percentage 
calculated from sectioned scaffold implant groups 7days after implantation, Each data 
point represents a mean + standard deviation (n=3). *P<0.05. Control group was 
significantly lower than the other three groups, P<0.05. 
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Fig 6 (A) 
 
Fig 6 (B) 
 
Fig.4.6. (A) Microscopic observation of the H & E stained tissue sections harvested of 
three scaffolds groups 7 days after implantation; 4 for full cross sections, and 10 for ⅹ ⅹ
high magnification views. (B) Tissue Penetration percentage calculated from sectioned 
scaffold groups 7days after implantation. Each data point represents a mean + standard 
deviation (n=3). *P<0.05, Control group was significantly lower than 
PLGA50-6.5K-1.5µg, PLGA50-1A-3µg and PLGA50-6.5K-6µg groups, P<0.05. There 
is no significant difference between control group and PLGA50-6.5K-0.3 µg group. 
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Fig 7(A) 
 
 
Fig 7 (B)  
 
Fig.4.7. (A) Microscopic observation of CD31 stained tissue sections harvested of three 
scaffolds groups 7 days after implantation (3µg bFGF/scaffold), 10 for high ⅹ
magnification views. (B) Blood vessel number calculated from sectioned scaffold groups 
7days after implantation. Each data point represents a mean + standard deviation (n=3). 
*P<0.05. Control group was significantly lower than the PLGA50-64K and 
PLGA50-6.5K groups, P<0.05, there is no significant difference between control and 
PLGA75-113K group. 
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Fig 8(A) 
 
 
Fig 8(B) 
Fig.4.8. (A) Microscopic observation of CD31 stained tissue sections harvested of three 
scaffolds groups 7 days after implantation, 10 for high magnification views. ⅹ (B) Blood 
vessel number calculated from sectioned scaffold groups 7days after implantation. Each 
data point represents a mean + standard deviation (n=3). *P<0.05. Control group was 
significantly lower than PLGA50-6.5K-1.5µg, PLGA50-6.5K-3µg and 
PLGA50-6.5K-6µg, P<0.05. There is no significant difference between control group and 
PLGA50-6.5K-0.3 µg group. 
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Chapter 5 
 
Dual release of bone morphogenetic protein-7(BMP-7) and platelet derived growth 
factor (PDGF)  from nano-fibrous PLLA scaffolds for periodontal tissue 
regeneration 
 
Introduction 
        Today, there are more than 50 million adults suffer from severe periodontitis in US. 
[1] Periodontitis, being the leading cause of tooth loss, is a common oral inflammatory 
infectious disease that can lead to the destruction of tooth supporting tissues such as 
alveolar bone, periodontal ligament and cementum.[2] Clinical periodontal therapies 
which mainly deal with eliminating inflammation sources and halting disease progression 
are not sufficient in complete regeneration of these multi-tissue tooth supporting 
structures and restoration of their full biological functions. [3] Therefore, it will be a great 
clinical impact to be able to restore these soft/hard multi tissue structures with dental 
tissue engineering approach. One important strategy in dental tissue engineering is to 
deliver signaling cues (e.g, growth factors) [4, 5] Bone morphogenetic proteins (BMPs) 
and Platelet derived growth factor (PDGF) are two important growth factors for dental 
tissue development. 
               Bone morphogenetic proteins (BMPs) are important growth factors in bone 
development and regeneration. [6, 7] BMP-2, BMP-4 and BMP-7 are the most effective 
ones in inducing bone formation at both orthotopic and ectopic sites among members of 
BMP family.[8-13] BMP-7 has been used in periodontal regeneration to promote 
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osteogensis, cementogenesis and periodontal ligament reconstruction. [14-16] However, 
despite BMPs' success in bone regeneration in animal and preclinical studies, their 
clinical success are limited due to their very high dosage requirement and the high cost 
and complications associated with it. [17, 18]  First possible solution to this problem 
could be the development of an appropriate BMP delivery system which enables a 
prolonged BMP release duration and protects BMP from proteolysis, denaturation and 
bioactivity loss to stimulate bone regeneration. [19-21] Second possible solution to this 
problem could be delivery of other growth factors alone with BMP to introduce 
synergetic effect and lower BMP dosage needed. [22] Platelet derived growth factor 
(PDGF) belongs to a multifunctional growth factor family. PDGF is composed of A, B, C 
and D polypeptide chains to form homo- or heterodimeric molecules. [23] PDGF can 
bind to two structurally related, intrinsic tyrosine kinase receptors (PDGF-Rα and PDGF-
Rβ) [24]to modulate cell migration and proliferation, prevent cell apoptosis and promote 
extracellular matrix synthesis and vascularization.[24-27] PDGF plays an important role 
in both organ development [26]and tissue repair. [28-30] Recombinant PDGF has been 
widely studied as a potential therapeutic agent to enhance periodontal wound repair [29] 
and regeneration preclinically [31-33]and clinically. [34, 35]  PDGF has been approved 
by FDA for enhancing bone repair of periodontal osseous defects. [29, 36] 
        Our previous researches developed novel PLGA nanospheres immobilized PLLA 
nanofibrous scaffold that could locally release single growth factor in a controlled 
fashion. [37, 38] Sustained release of BMP-7 from this PLLA scaffold induced 
significant ectopic bone formation [38]while sustained release of PDGF promoted 
neogenesis and angiogenesis successfully[39]. One advantage of this scaffold release 
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system is its ability to deliver multiple growth factors in distinct dosages and release 
rates. Therefore, we hypothesize that localized dual release of BMP-7 and PDGF from 
PLLA nanofibrous scaffold in a controlled fashion can significantly improve bone 
formation.  In the present study, we investigate the synergetic effect of controlled dual 
release of BMP-7 and PDGF from the novel PLLA nano-fibrous scaffolds in both mouse 
ectopic bone formation model and rat periodontal fenestration defect repair model. 
 
Materials and Methods 
Materials 
        RhBMP-7 and rhPDGF were kindly provided by Stryker Biotech (Hopkinton, MA) 
and Biomimetic Therapeutics (Franklin, TN) respectively. PLGA copolymers with 
LA/GA ratio of 50:50 (Lakeshore Biomaterials™, PLGA50-6.5K, Mw = 6.5 kDa; 
PLGA50-64K, Mw = 64KDa) were purchased from SurModics Pharmaceuticals Inc. 
(Birmingham, AL). Poly(L-lactic acid) (PLLA) with inherent viscosity of 1.6 dl/g was 
purchased from Boehringer Ingelheim (Ingelheim, Germany). Poly(vinyl alcohol) (PVA) 
(88 mol% hydrolyzed, MW = 25,000) were obtained from Polysciences Inc. 
Trifluoroacetic acid (TFA), Bovine serum albumin (BSA, Fraction V) and gelatin (type B 
from bovine skin) were obtained from Sigma Aldrich (St Louis MO). Dichloromethane 
(DCM), cyclohexane, hexane, tetrahydrofuran (THF) were purchased from Fisher 
Scientific (Pittsburgh, PA). 
 
Preparation of nanosphere-immobilized nano-fibrous scaffolds (NS-NFS) 
        Nanofibrous PLLA scaffolds were fabricated  as previously described. The scaffolds 
have high porosity of 98%.  They have macropores 250-425 µm in diameter and an 
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average interpore opening size of 116 µm. [40] For mouse subcutaneous implantation, 
highly porous scaffold were cut into circular disks with dimensions of 3.6 mm in 
diameter and 2 mm in thickness. For rat periodontal fenestration defect implantation, 
scaffolds were cut into rectangular cylinder with dimensions of 
3mm(L)×3mm(W)×2mm(H).  
        rhBMP-7 was incorporated into PLGA50-6.5K NS and rhPDGF was encapsulated 
into PLGA50-64K NS respectively using a double emulation techniques as previously 
described. [37, 38] PLGA NS were incorporated nanofibrous PLLA scaffolds using a 
post-seeding method. [37, 38] The growth factor amount in a scaffold was determined by 
the concentration of growth factor encapsulated in the PLGA NS and the amount of NS 
immobilized onto scaffold. NS containing gelatin/BSA was also incorporated into 
scaffolds and used as a control. After the post-seeding, the NS were further immobilized 
onto the scaffold wall by exposing the scaffold to a mixed vapor of hexane/THF (volume 
ratio 9/1) followed by vacuum drying for 3 days. The morphology of the scaffolds before 
and after the dual growth factors immobilization was observed using scanning electron 
microscopy (SEM, Philips SL30 FEG). 
 
Preparation of implants 
        For the mouse subcutaneous implantation study, 18 groups of scaffold implants 
(total 216 scaffold implants) were prepared as listed in table 5.1. Three BMP-7 dosages 
chosen for subcutaneous study were 0, 0.5 and 1.5 µg/scaffold, while the PDGF dosages 
were varied from 5 times to one fifth of each corresponding BMP-7 dosage. For rat 
periodontal fenestration defect implantation, four groups of scaffold implants (total 26 
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scaffold implants) were prepared as listed in table 5.2. The BMP-7 dosage was 1.5 
µg/scaffold, and the PDGF was kept at 3 µg/scaffold,   BMP/PDGF ratio was kept at 1:2. 
 
Mouse subcutaneous implantation 
        All animal procedures were approved by the University of Michigan Committee on 
Use and Care of Animals. For surgical procedures, general anesthesia was administered 
to six-week old, male C57/BL6 mice (Harlan Laboratories, Indianapolis, IN) by 
isoflurane inhalation. The backs of the animals were shaved and disinfected with a 10% 
povidone-iodine solution. Two midsagittal incisions (approx. 1 cm) were made on the 
dorsa of each mouse and two subcutaneous pockets were created using blunt forceps on 
each side of the incision, allowing four scaffolds to be implanted in each mouse. The NF-
scaffolds were carefully implanted into each pocket and the incisions were closed with 
surgical staples. At the end of each implantation period (3 or 6 weeks), the mice were 
euthanized by carbon dioxide overdose and the scaffolds were harvested for analysis.  
 
Rat periodontal fenestration defect implantation 
        General anesthesia was performed on rat with ketamine (90 mg/kg) and xylazine (10 
mg/kg). Ophthalmic ointment was applied to prevent irritation and reduce eye dryness 
during surgery. After reflecting the skin and the muscle by incision, full thickness 
mucoperiosteal flaps were elevated around the mandibular 1st molar. One periodontal 
fenestration defect was created on the buccal side of the mandible in each rat. The 
standard fenestration defect (3 × 2 mm2 dimension) exposed the distal root surface of the 
1st molar tooth. The cementum layer on the exposed root surface was removed and the 
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dentin surface was exposed. Each scaffold was implanted into the fenestration defect. The 
muscle and skin incisions were sutured and closed with surgical staples, respectively. 
Caprofen (5 mg/kg) was administrated subcutaneously as analgesic approximately 1 hour 
post-surgery. To maintain energy and prevent infection, animals were given a 5% 
dextrose solution in water containing 268 g/L ampicillin for one week post-surgery. 5 
weeks later, animals were euthanized with CO2 and biopsies were collected and fixed 
with 10% phosphate-buffered neutral formalin. All animal surgeries were performed 
under a protocol approved by the University Committee on Use and Care of Animals at 
the University of Michigan. 
 
Micro-computed tomography volumetric measurements 
        Both mouse subcutaneous implantation and rat periodontal fenestration defect 
implantation scaffold samples were subject to micro-computed tomography (micro-CT) 
Volumetric Measurements. Non-decalcified subcutaneous implant and mandible 
specimens were scanned at a resolution of 18x18x18 µm3 voxels using a µCT 100 cabinet 
cone-beam micro-CT system (Scanco USA, Inc, Wayne, PA).  GEHC MicroView 
Analysis+ 2.1.2® software (GE Healthcare, Little Chanlfont, UK) was used to create 
three-dimensional (3D) reconstructions of harvested specimens as previously described 
[41]. Specimen scans were then oriented into standardized position. For subcutaneous 
implant specimens, the region of interest (ROI) for analysis of mineralized tissue 
formation encompassed the entire specimen.  The ROI for analysis of mineralized tissue 
formation in mandible specimens was created using the horizontal length of entire defect 
and vertical length of the recessed surface along the exposed distal root of the first molar 
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[42].  To distinguish between mineralized and non-mineralized voxels, the threshold 
gray-scale value for each subcutaneous implant specimen was determined by one masked 
and calibrated examiner, while the other masked and calibrated examiner determined the 
threshold value for each of the mandible specimens. The average threshold gray-scale 
value was calculated and used as the representative value to derive the following 
parameters: tissue mineral content (TMC, mg), and tissue mineral density (TMD, mg/cm3) 
for implant and mandible specimens. Bone volume fraction represents the ratio between 
the bone volume and total ROI volume. TMC represents the amount of calcified tissue 
present, while TMD is a measure of bone quality – represented by the formula TMC/BV.   
 
Calcium content measurement 
        Mouse subcutaneous implantation samples were subject to calcium content 
measurement. After MicroCT scanning of non-decalcified subcutaneous implant, the 
implants were rinsed with MilliQ water, lyophilized, dissolved with 10 ml HClO. One 
microlitter of the resulting solution was added to 5 ml mix solution of calcium buffer 
reagent and calcium color reagent in the calcium measure kit (Pointe Scientific, Inc. 
Canton, MI). The solution was incubated at room temperature for 5 minutes, and read at 
650 nm in UV spectrophotometer. Five mg/ml of calcium chloride solution was used as a 
standard.  
 
Histological examination 
        Both mosue subcutaneous implantation and Rat periodontal fenestration defect 
implantation scaffold samples were subject to histological examination. For mice 
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subcutaneous study, after 3 and 6 weeks, scaffolds implants were harvested.  They were 
fixed in neutral buffered 10% formalin and then embedded in paraffin. Five-micrometer 
sections were cut and stained with hematoxylin and eosin (H&E) for light microscopic 
observation. [15, 43] 
        For rat periodontal fenestration defect implantation study, regenerated tissue on 
scaffolds was harvest 2 and 5 weeks after surgery and were then placed into Bouin’s 
fixative, decalcified with 10% vol/vol acetic acid, 4% vol/vol formaldehyde, 0.85% NaCl 
for 2 to 3 weeks and then embedded in paraffin. The specimens were cut into 4 to 5 µm 
coronal sections and stained with hematoxylin and eosin (H & E) or toluidine blue for 
visualization by light microscopy. 
        Periodontal tissue repair and regeneration was determined using computer-assisted 
image analysis. Images of specimens were captured at 2, 4, 10, and 20x magnification 
using a Nikon Eclipse 50i microscope (Nikon Inc., Melville, NY) fitted with a Nikon 
Digital Sight DS U1 camera (Nikon Inc., Melville, NY). Histomorphometric analysis was 
performed using NIS Elements Basic Research Imaging software (Nikon Inc., Melville, 
NY).  A single masked, calibrated examiner examined all of the slides. The parameters of 
periodontal regeneration measured included: 1) length of new cementum on the distal 
root of the first molar in mm (measured at 5-week time point only); 2) length of new 
bridging bone measured from the borders of the original osseous defect (mesially-distally) 
in mm (2 and 5 week time points); 3) area of new bone associated with the osseous defect 
and nanofibrous scaffold in mm2 (2 and 5 week time points). Mean values were generated 
for each of the groups and significant differences were determined using an analysis of 
variance. 
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Results 
Characterization of dual BMP-7/PDGF nanosphere-immobilized scaffold 
        Fig 5.1 shows that the 3D multi-level porous architecture of PLLA scaffold after 
BMP and PDGF containing nanosphere incorporation.  Regular spherical macropores 
(250-425 µm in diameter) and interpore openings (approximately 100 µm in diameter) 
remained open and unaltered. After NS incorporation, the nanofibers (50-500 nm in 
diameter) on the scaffold wall were adhered with PLGA MS/NS. PLGA MS/NS were 
uniformly distributed throughout the scaffolds. In vitro release studies of single BMP-7 
[38] or PDGF [37] from PLLA nanofibrous scaffold were performed and the results were 
published in previous papers. Briefly, the release profiles of single protein from 
nanospheres in scaffold was determined by PLGA formulation. 48% of BMP-7 was 
released from PLGA50-6.5K NS scaffold in initial first day burst release and 78% of 
BMP-7 released within the first two weeks. [38] PLGA50-64K NS scaffold released 
PDGF in a multi-phasic pattern.  23% of PDGF were released in initial first day burst 
release and 40% released within two weeks, followed by a 3 weeks slow release (0.3% 
per day). From week 5 to 8, there is another fast release of 20% which corresponds to 
PLGA NS degradation. [37, 38] 
 
Mouse subcutaneous implantation results 
        Three weeks after subcutaneous implantation, Fig 5.2 A and B showed that the 
highest calcium content and highest Micro-CT tissue mineral content were found in the 
BMP-7 (1.5 µg/scaffold) +PDGF (3 µg/scaffold), BMP-7/PDGF 1:2 group (group 17). It 
was noted that both the calcium content and tissue mineral content were much lower in 
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BMP-7 (1.5 µg/scaffold) single release group (group 3), even though group 17 and group 
3 had the same BMP dosage. It was also observed that these two values were lower in 
group 14, 15, 16, 18, even though they shared the same dosage of BMP-7 with group 17 
but with different BMP/PDGF ratio. In consistence with calcium content and micro-CT 
measurement, Fig 5.3 of microscopic observations of the H&E stained tissue sections of 
scaffolds harvested 3 weeks after subcutaneous implantation showed robust neo bone 
formation (stained pink ) in scaffold group 17.  Although tissues have penetrated all the 
scaffold groups (1-18), no bone formation was found in control groups (group 1) and 
PDGF single release groups (4, 5, 6, 7, 8) While any groups with BMP-7 release showed 
some neo-bone formation, group 17 with BMP-7 (1.5 µg/scaffold) +PDGF (3 
µg/scaffold), BMP-7/PDGF 1:2 ratio showed highest amount neo-bone formation.  After 
six weeks of subcutaneous implantation, Fig 5.4 of microscopic observations showed 
there is still no bone formation found in control group (1) or low dosage PDGF single 
release group (4-7). Cells presented in those scaffolds are mainly fibroblasts and 
macrophages. High dosage PDGF single release group (8) showed some neo-bone 
formation but the amount is smaller compared to any BMP-7/PDGF dual release group. 
Group 17 showed significant neo-bone formation and was one of the best groups in terms 
of calcium content and micro-CT tissue mineral content. (Fig 5.2 A and B) These results 
suggest that release of BMP-7 from PLLA nanofibrous scaffolds with proper controlled 
delivery system induces ectopic bone formation. The release of PDGF from the scaffold 
significantly enhances BMP induced ectopic bone formation. The best synergetic ectopic 
bone forming effect of the dual release of these two growth factors occurred in scaffold 
group 17 with BMP-7 (1.5 µg/scaffold) +PDGF (3 µg/scaffold), BMP-7/PDGF 1:2. This 
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dosage combination was used as the optimal dosage combination for rat periodontal 
fenestration defect repair study. 
      
Rat periodontal fenestration defect repair results 
Histology examination 
        Fig 5.5 of microscopic observations of the H&E stained tissue sections of scaffolds 
harvested 2 weeks implantation showed minimal bridging and no neo cementum 
formation in all scaffolds groups, which was normal for such an early time point. 
However, bone formation lateral to the defect (indicated by open arrow) was observed in 
BMP single release groups (e) as small and scattering distributed bone tissues that were 
stained pink.  BMP-7/PDGF dual-release groups (g) showed much more larger and 
complete pink bone tissue structures, which indicated most extensively neo bone 
formation.  Fig 5.6 showed a close look at these scaffolds at defect regions and lateral 
defect border at higher magnifications. It was also observed that the dual release group 
induced higher bone formation (with largest integrated pink bone areas) and more blood 
vessel formation (with larger number of red vessel structure). Consistent to histological 
observation, histomorphometric analysis at 2 weeks (Fig 5.7) confirmed that BMP-
7/PDGF dual release scaffold groups resulted in significant increase in new bone area 
above control and PDGF single-release groups, and larger bone area than BMP-7 single 
release group, although the difference was not significant at this time point. 
        Fig 5.8 of microscopic observations of the H&E stained tissue sections of scaffolds 
harvested 5 weeks implantation showed that bridging and bone formation was observed 
in all scaffold groups, with pink bone tissue areas observed in all experiment groups. 
112 
 
However, the dual release group (g) formed integrated neo-bone structure to occupy the 
whole defect region and the bone bridging in this group is continuous while the bone 
bridging in all the other groups was disrupted and the bone structures are incomplete. 
New cementum formation was also observed in all groups at this time point. Fig 5.6 
showed a close look at these scaffolds at defect regions and lateral defect border at higher 
magnifications. It was confirmed that dual release group forms complete large bone to 
cover the whole defect area, while neo-formed bone tissues were discontinuous and 
scattered inside the defect in other groups. Dual release group also showed most obvious 
blood vessel formations. In accordance to histology micrograph observation, 
Histomorphometric analysis at 5 weeks (Fig 5.10) confirmed that BMP-7/PDGF dual 
release scaffold groups resulted in significant improvements in new bone area above all 
the other groups at this time point. 
 
Quantitative and qualitative micro-CT analysis 
        In sectional views of micro-CT images, (Fig. 5.11), sagittal views of the 
representative three-dimensional (3-D) micro-CT isosurface images demonstrated the 
differences in mineralized tissue healing and bone regeneration between the experimental 
groups. While distal root was still exposed in control scaffold only group, PDGF and 
BMP single release groups, it was not exposed anymore and covered by regenerated bone 
in BMP-7/PDGF dual release group after 5 weeks defect repair. The dual BMP-7/PDGF 
release group presented larger amounts of tooth supporting mineralized tissue inside of 
the marked ROIs in both transverse and coronal sections compared to the control group 
and BMP-7, PDGF single release group. Although periodontal osseous defects with 
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standardized dimensions were created, mineralized tissue formation was not limited to 
the defect site and was sometimes present along the native bone (denoted by white 
dashed lines) on the buccal side of the mandible. It was obvious that dual release group 
had most bone formation extended beyond the bony envelope. 
        In accordance to the micro-CT sectional view images, qualitative analysis (Fig 5.12 
A) confirmed that dual release scaffold groups induced significant higher amount of 
mineralized tissue formation in the total defect area of all the experiment groups. These 
tissue mineral content includes both tooth supporting tissue and non-tooth supporting 
tissues. Overall, none of the experimental groups demonstrated statistically significant 
differences in tissue mineral density at 5 weeks.  
 
Discussion 
        The major goal of periodontal tissue engineering is to reconstruct tooth supporting 
multi-tissue structures destroyed by either injury or severe chronic periodontitis. One 
important strategy is to deliver growth factor to periodontal lesions to achieve periodontal 
tissue repair. Although success has been achieved by deliver of single growth factor to 
periodontal lesions to stimulate partial periodontal tissue regeneration, [14, 32, 44] their 
clinical utility was limited. One major reason is that periodontal tissue regeneration, for 
example periodontal bone regeneration is a multi-step process that requires the 
stimulation from multiple biological factors including (inflammatory, angiogenetic and 
osteogenetic) in a dynamic and coordinated manner. So, the periodontal bone 
regeneration relied on single delivery of BMP-7 is not sufficient for clinical applications.  
Thus, in order to significantly to improve bone formation, multiple growth factors 
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delivery in distinct dosage and rate to mimic natural regeneration process is absolutely 
needed. PDGF was found to stimulate periodontal wound repair [29] and enhance bone 
regeneration of periodontal osseous defects. [29, 36] In addition, our previous research 
demonstrated that controlled delivery of PDGF stimulates neogenesis and angiogenesis, 
[37, 39] which usually couples with bone regeneration. [45] Therefore, angiogenesis 
factor such as PDGF could be applied along with BMP in periodontal tissue regeneration 
to improve BMP induced bone repair. Early angiogenesis can be improved by the release 
of PDGF, thus, more nutrients, growth factors and oxygen are transported to the defect 
site by larger number of newly-formed blood vessels, which favors neo bone formation.  
Invasion of blood vessel is also desirable in cartilage to bone transformation during 
endochondral ossification process since they transport both stem cells and osteo-
progenitors. [46] These cells deposit bone on cartilage matrix at the later stage of 
endochondral ossification which favors more bone formation as a final outcome. 
        However, this promising strategy has not achieved significant clinical success yet 
mostly due to the lack of localized controlled delivery system which can release multiple 
growth factors with distinct dosages and rates, since the synergistic effect of angiogenetic 
factor with BMP to promote bone regeneration can only be achieved when a defined 
suitable release dosage and kinetics are applied. [47-50] 
        Previously, a nanofibrous tissue engineering scaffold has been developed in our lab 
which can serve as both a growth factor delivery vehicle and a 3-dimensional cellular 
construct for multiple tissue regeneration. [37, 38, 40, 51] Both BMP-7 and PDGF have 
successfully been delivered from this nanofibrous scaffold with controllable release 
dosage and kinetics and these released growth factors have successfully exerted their 
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biological functions in vivo. [38, 39] The capability to deliver multiple growth factors 
with distinct release dosages and kinetics is one of the advantage of this type of scaffold. 
Our data has shown that ectopic bone formation was increased by the dual release of 
PDGF along with BMP-7 from this scaffold system and the improvement depended on 
the ratio of the two growth factors. The most improvement came with the combination of 
BMP-7 (1.5 µg/scaffold), PDGF (3.0 µg/scaffold), BMP-7/PDGF ratio 1:2. (Fig 5.2-5.4). 
Our data also showed that using this dual release scaffold with BMP-7/PDGF 1:2 ratio in 
rat periodontal fenestration defect repair model, improved periodontal repair was 
observed with this dual release group compared to the control and single BMP-7 and 
PDGF release groups. In dual release group, more mineralized tissues were regenerated 
to fill more spaces in the total defect region (Fig 5.7 and Fig. 5.10) and the distal root was 
no longer exposed, while in other groups, part of root was still exposed. (Fig 5.11). The 
bridging along the defect in dual release group was much more continuous than in other 
groups. (Fig 5.8).  
        Our data suggested that early angiogenesis was improved by the release of PDGF in 
dual release group, with more new blood vessels formed. (Fig 5.6). These new formed 
blood vessels transported more growth factors, nutrients and oxygen to the defect site to 
promote neogenesis. It was also observed more blood vessels were presented close to 
newly formed bone areas in dual release scaffold groups, (Fig. 5.10) which proved that  
the invasion of blood vessels also promoted bone marrow cells invasion and deposition of 
bone matrix on cartilage matrix during later stage of endochondral ossification. All these 
effects were combined together and resulted in stronger bone formation in dual release 
group.         
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        Besides, It was also noted that when the dual release scaffold system was applied in 
periodontal defect repair, mineralized tissue formation was not limited to the defect site 
which demonstrated the potential of this scaffold to be used in much larger sized osseous 
defect repair applications.  
 
Conclusion 
        We have developed a novel PLLA nanofibrous scaffold which can fulfill localized 
dual release of BMP-7 and PDGF in a controlled fashion with distinct dosage and release 
kinetics. Both ectopic bone formation and periodontal fenestration defect regeneration 
was significantly improved with this dual release scaffold system. The improvement was 
dependent on the dosage and the release kinetics of the two growth factors. This 
nanofibrous scaffold with its controlled multiple growth factor delivery capacity can be 
applied in various tissue regeneration and large sized defect repair. 
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Fig5.1. SEM micrograph of PLLA nanofibrous scaffold before and after PLGA50-6.5K 
NS containing BMP-7 and PLGA50-64K NS containing PDGF incorporation (BMP-7: 
1.5 µg/scaffold and PDGF: 3 µg/scaffold). PLLA nanofibrous scaffold before NS 
incorporation at 100× (A) and 5000× (B) PLLA nanofibrous scaffold after dual growth 
factors NS incorporation at 100× (C) and 5000× (D) 
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Fig 5.2. (A) Results of calcium content measurement  (B) Results of Micro-CT mineral 
content measurement of scaffolds harvested after 3 and 6 weeks subcutaneous 
implantation. 
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Fig5.3. Microscopic observations of the H&E stained tissue sections of scaffolds 
harvested 3 weeks after subcutaneous implantation at magnification 40× full cross 
sections.  
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Fig 5.4. Microscopic observations of the H&E stained tissue sections of scaffolds 
harvested 6 weeks after subcutaneous implantation at magnification 40× full cross 
sections.  
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Fig. 5.5. Dual release of PDGF/BMP-7 from scaffolds stimulations periodontal defect 
repair and bone formation after 2 weeks. Panels a, c, e, g show 4x magnification of the 
global defect region at 2 weeks following surgery. The black arrows indicate the edges of 
the original osseous lesion. Open arrows show areas of bone formation. Panels b, d, f, h 
show a 10x view of the denuded tooth root surface at 2 weeks. In these panels, white 
asterisks indicate scaffold and closed arrow heads indicate areas of close approximation 
to tooth surface.  
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Fig 5.6. Descriptive histology within the defect region and lateral to the defect at 10x and 
20x magnification. (2 weeks) White asterisks indicate nanofibrous scaffold material. 
Black asterisks indicate new bone formation. Open arrows point to blood vessels. 
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Fig.5.7. PDGF/BMP-7 dual-release from nanofibrous scaffolds stimulates osteogenesis at 
2weeks. At 2 weeks, PDGF/BMP7 dual-release resulted in statistically significant 
improvements in new bone area above control and either BMP-7 or PDGF release alone 
(*P<0.05).  
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Fig.5.8. Dual release of PDGF/BMP-7 from scaffolds stimulations periodontal defect 
repair and bone formation after 5 weeks. Panels a, c, e, g show 4x magnification of the 
global defect region at 14 days following surgery. The black arrows indicate the edges of 
the original osseous lesion. Open arrows show areas of bone formation. Panels b, d, f, h 
show a 10x view of the denuded tooth root surface at 5 weeks. Cementum formation was 
observed at 5weeks time point. In these panels, white asterisks indicate scaffold and 
closed arrows indicate areas of close approximation to tooth surface. 
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Fig.5.9.  Descriptive histology within the defect region and lateral to the defect at 10x and 
20x magnification. (5 weeks) White asterisks indicate nanofibrous scaffold. Black 
asterisks indicate new bone formation. Open arrows demonstrate blood vessels. 
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Fig.5.10. PDGF/BMP-7 dual-release from nanofibrous scaffolds stimulates osteogenesis 
at 5 weeks. At 5 weeks, dual release resulted in statistically significant improvement in 
new bone area above all groups (‡ P<0.001). The 5-weeks dual-release samples also 
exhibited statistically significant increase in new bridging bone compared with BMP-7 
single-release († p<.01).  
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Fig.5.11. Micro-CT analysis for evaluation of mineralized tissue formation in 
standardized surgically created mandibular-alveolar bone defects.  In the transverse 
sections (green dashed line), yellow dashed lines mark the borders of the ROI, while red 
triangles demarcate the recessed tooth-root surface region that resulted from removal of 
cementum layer.  Coronal slices (blue dashed line) also provide an alternative view of the 
ROI borders identified by the yellow dashed lines. In both transverse and coronal 
sections, varying amounts of tooth-supporting mineralized tissue is evident inside of the 
marked ROIs. Bone formation extending beyond the bony envelope is denoted by white 
asterisks.  
 Fig 5.12. (A) Micro-CT tissue mineral content  (TMC) results of all scaffolds groups in 
total defect region after 5 weeks 
density of all scaffolds groups in total defect region after 
repair. ( P<0.05) 
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Table 5.1 Experiment design of BMP-7/PDGF dual releasing PLLA scaffold for 
subcutaneous implantation. 
 
 
 
 
 
 
 
 
 Group BMP-7 (fast) 
µg/scaffold 
PDGF-BB 
(slow) 
µg/scaffold 
BMP/PDGF 
BMP-7 (0 µg) 1 0 0  
2 0 0.1  
3 0 0.5  
4 0 1.5  
5 0 3  
6 0 7.5  
BMP-7 (0.5 µg) 7 0.5 0  
8 0.5 0.1 5:1 
9 0.5 0.25 2:1 
10 0.5 0.5 1:1 
11 0.5 1 1:2 
12 0.5 2.5 1:5 
BMP-7 (1.5 µg) 13 1.5 0  
14 1.5 0.3 5:1 
15 1.5 0.75 2:1 
16 1.5 1.5 1:1 
17 1.5 3 1:2 
18 1.5 7.5 1:5 
1. PDGF-BB and BMP-7 were encapsulated in PLGA microspheres which are 
incorporated into PLLA nano-fibrous scaffold. 
2. Scaffold size: 3.6 mm in diameter, 2 mm in thickness, time points: 3 weeks, 6 
weeks 
3. 6 scaffolds/time point/group (18), total 216 scaffolds, 60 mice (6 extra), 3 
scaffolds/time point/group for Micro-CT and histology (108 scaffolds), 3 
scaffolds/time point/ group for Ca content (108 scaffolds). 
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Table 5.2 Experiment design of BMP-7/PDGF dual releasing PLLA scaffold for 2 weeks 
rat periodontal fenestration defect implantation.  
 
 Group BMP-7 fast 
(ug/scaffold) 
PDGF-bb slow 
(ug/scaffold) 
BMP/PDGF 
control 1 0 0  
 2 1.5 0  
 3 0 3.0  
 4 1.5 3.0 1:2 
1. PDGF-BB and BMP-7 were encapsulated in PLGA microspheres which are 
incorporated into PLLA nano-fibrous scaffold. 
2. Scaffold size: 3 mm(L)*3mm(w)*2mm(H), time point: 2 week 
3. 6 scaffolds/time point/group (4), total 48 scaffolds, 26 rats (2 extra), 6 
scaffold/time point/group for histology (24 scaffolds) 
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Table 5.3 Experiment design of BMP-7/PDGF dual releasing PLLA scaffold for 5 weeks 
rat periodontal fenestration defect implantation.  
 
 Group BMP-7 
(ug/scaffold) 
PDGF-bb 
(ug/scaffold) 
BMP-PDGF 
control 1 0 0  
 2 0 3.0 (S)  
 3 1.5(F) 0  
 4 1.5(F) 3.0(S) 1:2 
1. PDGF-BB and BMP-7 were encapsulated in PLGA microspheres which are 
incorporated into PLLA nano-fibrous scaffold 
2. Scaffold size: 3*3*2 (18 mm3), rat periodontal defect model, time point: 5 week 
3. 6 scaffolds/time point/group (4), total 24 scaffolds, 28 rats (4 extra), 6 
scaffold/time point/group for Micro-CT and histology (24 scaffolds) 
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Chapter 6 
Fabrication of an anisotropic bilayered composite scaffold to induce zonal 
development of cartilage tissue 
 
Introduction 
      Cartilage is a connective tissue consisting of chondrocytes embedded in a 
complicated extra-cellular matrix (ECM) composed of collagen, glycosaminoglycans, 
fibronectin, elastin, laminin and water [1]. Articular cartilage, being the most abundant 
cartilage type, can be divided into four zones, namely the superficial, middle, deep and 
calcified zones. Each zone has its distinctive matrix organization, chondrocyte 
morphology and biochemical compositions [2], which plays important roles in its 
corresponding biomechanical function. Accordingly, the functional recovery of articular 
cartilage defect requires the reconstruction of the damaged zonal structure. Unfortunately, 
cartilage tissue shows little tendency of self-repair and regeneration, owing to its lack of 
internal vascular network and low mitotic activity of chondrocytes [3, 4]. Consequently, 
articular cartilage injuries caused by osteoarthritis or trauma often persist for years and 
result in scar formation, which is structurally and functionally inferior to normal cartilage 
and eventually lead to further cartilage degeneration (i.e., Secondary osteoarthritis) [5]. 
Several strategies have been applied to treat these cartilage related diseases including 
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resection, cartilage shaving or other surgical intervention, bone marrow stimulation and 
tissue grafts. Despite some encouraging clinical results, these methods are usually 
associated with drawbacks like pain reoccurrence and donor site morbidity [2, 6]. Over 
the past decades, cartilage tissue engineering has emerged as a promising approach in 
treatment of these diseases, which involves the expansion of isolated chondrocytes 
followed by delivery to the cartilage defects to promote in situ tissue regeneration [7, 8]. 
Efforts have been made to develop appropriate cell delivery scaffolds to create an 
advantageous artificial ECM microenvironment for chondrocytes to adhere and maintain 
their differentiated phenotype and function. Various naturally derived and synthetic 
polymers have been tested as scaffold materials [9-11] and two types of scaffolding have 
been widely applied: porous foams and hydrogels [12]. Hydrogels are highly hydrated 
polymeric networks due to chemical or physical crosslinking of individual polymer 
chains [13]. Hydrogels are used as cartilage engineering scaffold materials because they 
can mimic the in vivo chondrocyte growth environments and preserved their 
differentiated phenotypes due to the highly hydrated structure and maintenance of 
rounded cell shape [14]. However, their poor mechanical strength limits their applications 
in load-bearing areas such as articular cartilage defects [12]. Besides, it remains difficult 
to create a zonal articular cartilage structure with hydrogel materials, despite limited 
success to introduce three dimensional (3D) patterning structure to hydrogels to alter their 
normal isotropic structure [15]. Porous foams, in contrast, usually have better mechanical 
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properties and are easier to design architectural structure [12]. However, chondrocytes 
cultured on most of the porous foam scaffolds lost their rounded morphology quickly and 
therefore de-differentiated [16, 17]. In our previous study, macro-porous PLLA scaffolds 
with nano-fibrous (NF) matrix structure were shown to support chondrogenic 
differentiation of human bone marrow-derived mesenchymal stem cells (hMSCs). Cells 
showed a more rounded shape on the NF matrix and the porous NF scaffolds were able to 
support long-term 3D cartilaginous development [18], indicating the importance of 
bio-mimicking NF structures in cartilage engineering. Electrospinning is another 
commonly used method to create porous NF or micro-fibrous architecture [19, 20]. 
However, the pores are too small to allow deep cell penetration when the fibers are at the 
nano-scale. Therefore the electrospun NF mesh is more suitable for regeneration of the 
thinner surface layer of cartilage.  
    In this study, a two-layered composite scaffold was fabricated, which combined the 
two nano-fiber fabrication techniques, with a thin electrospun NF top layer mimicking 
the superficial zone and a phase-separated NF bottom layer mimicking the middle zone. 
And the effect of the anisotropic architecture of composite scaffolds on in vitro 
chondrogenesis of hMSCs was investigated.  
 
Materials and methods 
Materials 
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      Poly (L-lactic acid) (PLLA) with inherent viscosity of 1.6 dl/g was purchased 
from Boehringer Ingelheim (Ingelheim, Germany). D-fructose (m.p. 119-122°C) is from 
Sigma (St. Louis, MO). Tetrahydrofuran, acetone, cyclohexane, hexane and 
dichloromethane were purchased from Fisher Scientific (Pittsburgh, PA). 
 
Fabrication of NF PLLA composite scaffolds  
      The composite scaffold is composed of two layers: a top layer fabricated by 
electrospinning method and a bottom layer fabricated by temperature induced phase 
separation method combined with sugar sphere template and leaching technique. The 
schematic diagram of fabrication process is illustrated in Figure 1. Fabrication of bottom 
phase-separation layer has been described previously [21]. Briefly, 10 wt/v% 
PLLA/tetrahydrofuran (THF) solution was cast into an assembled sugar sphere template 
(sphere diameters were 125-250 µm, 250-425 µm and 425-600 µm respectively for small, 
medium and large pore scaffolds) under vacuum. The polymer-sugar construct was phase 
separated at -20°C overnight and then immersed into cyclohexane to exchange THF for 
2 days. The construct was then freeze-dried and the sugar sphere templates were leached 
out in distilled water to obtain highly porous scaffolds. Scaffolds were cut into circular 
disks with dimensions of 3.6 mm in diameter and 1 mm in thickness. A top layer of PLLA 
NF or micro-fibrous mesh was then electrospun onto the bottom layer to fabricate 
composite scaffolds. Briefly, The PLLA was dissolved in chloform/acetone mixture (2:1 
V/V) with a concentration of 6, 8 or 12 wt/v%. The prepared PLLA solution was then fed 
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into a plastic syringe with a needle (inner diameter of 0.18 mm). A syringe pump (Model 
# 78-01001, Fisher Scientific) was used to feed the solution to needle at a feed rate of 1.5 
mL/hr. An external voltage of 18kV was applied to the needle using a high-voltage power 
supplier (Model # ES30P-5w, Gamma High voltage). The phase separated bottom layer 
was placed on a grounded collection plate of aluminum foil, located at a fixed distance of 
12 mm from the needle tip. After the fabrication of top electrospun layer with desired 
thickness (50µm-250µm) by adjusting the total electrospinning time, the composite 
scaffold was subjected to a vapor of a mixture of hexane/THF (9:1 V/V) for 30 min to 
increase the bonding between the two layers. After that, the composite scaffolds were 
vacuum-dried for 3 days to remove the remaining solvent. Some of the scaffolds were 
sterilized with ethylene oxide for cell culture studies.      
 
Characterization of scaffolds 
      The thickness of the top layer and bottom layer was measured with a micrometer. 
The morphology of the composite scaffold was examined using a scanning electron 
microscope (SEM, Philips XL30 FEG). The measurement of nano-fiber diameters was 
performed according to a previous report [22]. Fiber orientation was counted with a 
representative cross-section of composite scaffolds. 
 
Cell seeding and culture 
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      Human bone marrow-derived mesenchymal stem cells (hMSCs) were obtained 
from Lonza Walkersville, Inc. (Walkersville, MD). The cells were cultured according to 
the manual provided by the supplier. Scaffolds (3.6 mm in diameter and 1 mm in 
thickness) were soaked in 70% ethanol for 30 min, washed three times with PBS for 30 
min each, and twice in complete medium for 2 hr each on an orbital shaker at 75 rpm. 
2.5×105 cells were seeded into each scaffold from the side of phase-separated layer. To 
induce chondrogenesis, cell-seeded scaffolds were transferred to 15 ml polypropylene 
culture tubes and maintained in 0.5 ml chondrogenic medium supplemented with 10 
ng/ml TGF-β1 (R&D Systems Inc., Minneapolis, MN). The medium was changed twice a 
week. 
 
 
Histological observations 
      Constructs were washed in PBS, fixed with 3.7% formaldehyde in PBS overnight, 
dehydrated through a graded series of ethanol, embedded in paraffin, and sectioned at a 
thickness of 5 µm. For histological observations, sections were deparaffinized, rehydrated, 
and stained with hematoxylin-eosin or Alcian blue. For each layer, 2 areas were randomly 
selected and the cell numbers per area were counted. Cell orientation in the top 
electrospun layer was counted with a representative cross-section of constructs. For 
immunofluorescence staining of collage type II, rehydrated sections were pre-treated with 
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pepsin solution for 15 min, incubated with collage type II antibody at 1:100 dilutions for 
1 hour, rinsed with PBS three times for 5 min each, then incubated with FITC-conjugated 
secondary antibody at 1:100 dilution for 1 hour. After rinsing three times with PBS, 
sections were mounted using mounting medium containing 
4’-6-diamidino-2-phenylindole (DAPI) and observed under a fluorescence microscope.    
  
Statistical analysis 
      For cell culture experiments, numerical values were reported as mean ±S.D. (n=3). 
To test the significance of observed differences between the study groups, the Student’s 
t-test was applied. A value of p < 0.05 was considered to be statistically significant 
different. 
 
Results 
Morphological properties of composite scaffolds 
      A composite scaffold was designed with a top layer made using an electrospining 
technique and a bottom layer made using a temperature induced phase separation method 
combined with porogen (sugar sphere) templating and leaching, mimicking the 
architectural structures of articular cartilage superficial zone and middle zone. 
Fig.6.2A-C show the electrospun NF layers with different thickness (50 µm, 150 µm and 
250 µm respectively) formed on a macro-porous phase separated bottom layer (pore size: 
125-250 µm in diameter) under the conditions of 6wt/v% PLLA concentration and 
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various electrospinning times. With the increase of electrospinning time, the thickness of 
top electrospun NF layer increases. Fig.6.2D-E show a 50 µm thick electrospun NF layer 
formed on macro-porous phase-separated bottom layers with different pore sizes 
(250-425 µm and 425-600 µm in diameters respectively). The results demonstrated the 
formation of PLLA bilayered composite scaffolds with tunable macro-pore size of the 
bottom layer and thickness of the top layer. Fig.6.2F-G show the random shaped pore 
structure and NF morphology of electrospun top layer, and Fig.6.2H-I show the uniform 
macro-porous structure and NF morphology of the phase-separated bottom layer. The 
fiber diameters of this layer are in the range of 50-500nm.  
    Fig. 6.3 shows the NF layers electrospun from PLLA solutions with various polymer 
concentrations (Fig. 6.3A-3C, from 6wt/v% PLLA, Fig. 6.3D-3F, from 8wt/v% PLLA, 
Fig. 6.3G-3I, from 12wt/v% PLLA) formed on a macro-porous phase-separated bottom 
layer (pore size: 250-425µm in diameter). The average fiber diameters of electrospun NF 
layers increased with the increase of PLLA concentrations from 155nm (6wt/v% PLLA) 
to 1750nm (12wt/v% PLLA), listed in table 6.1. The average pore sizes in the electrospun 
NF layers also increased with the increase of PLLA concentration. The formation of 
beads was observed in the electrospun NF layers at 6wt/v% PLLA (Fig 3A-C), which is a 
common phenomenon that occurs when low polymer concentration solution is used to 
electrospin nanofiber mat due to its low viscosity [23]. Fig 6.3J showed that the majority 
of the electrospun fibers in top layer orientated parallel to the scaffold surface plane. The 
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top and bottom layers of the composite scaffolds have distinctive pore structures and fiber 
morphologies shown in both Fig.6.2. and Fig.6.3. The structural parameters of the two 
layers can be adjusted independently with their respective processing parameters.  
 
Chondrogenesis of hBMSCs on composite scaffolds 
      The hBMSCs were seeded from the side of macro-porous phase-separated bottom 
layer. Then the scaffold was flipped over and the electrospun NF layer was positioned up 
during cell culture. The hBMSCs grew throughout the whole composite scaffolds after 
2wk and 4wk of chondrogenic culture (Fig.4A-B) and an anisotropic distribution of cells 
and cell morphology developed. The cells in the electrospun top layer were more 
flattened compared to the more rounded shape of the cells in macro-porous 
phase-separated bottom layer. The top layer has higher cell density than bottom layer 
during the culture period (Fig.6.4C). Consistent with the more paralleled orientation of 
PLLA fibers in top layer, the cells were more aligned along the constructs surface plane 
(Fig.6.4D). Alcian blue staining (Fig.6.5A) and collagen type II immunofluorescence 
staining (Fig.6.5B) further showed the differentiated cells began to deposit cartilagous 
ECM into the scaffold more isotropically distributed in the bottom layer and an 
orientation more in parallel to the surface plane in the top layer. 
 
Discussions 
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      This study aims at reconstructing cartilage zonal structure by advanced scaffold 
design and subsequent modulation of the chondrogensis process of stem cells. Attempts 
to grow cartilage tissue with native zonal structure have been made by mimicking 
specific zonal cartilage separately on different specific hydrogel scaffolds [27], by 
creating spatial gradients of growth factor concentration [28], or scaffold chemical 
composition [29] inside scaffold, and by using different chondrocytes from different 
cartilage zones [30]. Chondrogenesis is a tightly controlled development event, involving 
multiple steps including condensation of mesenchymal stem cells, chondrogenic 
commitment, and differentiation into chondrocytes. Studies have showed that the 
phenotype of cells can be affected by the physical architecture of scaffolds [24-26]. 
However, few studies have applied this concept to establish the anisotropic zonal 
morphology of articular cartilage tissue in a single scaffold, due to the complexity of the 
structures.  
    In this study, we designed a NF composite scaffold to support chondogenic 
differentiation of hBMSCs and facilitated zonal development. The results were consistent 
with our earlier publication that NF matrix structures improved chondrogenic 
differentiation [18]. This novel bilayered composite scaffold system offers several 
advantages: the composite scaffolds were fabricated from one single biocompatible and 
biodegradable polymer PLLA, and the scaffolds were cultured with one single cell source, 
which simplified the fabrication and culture process. The scaffolds created a complex 
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zonal structural microenvironment for chondrogensis. The two layers of the scaffold were 
fabricated with different pore shape, pore size, fiber morphology, fiber diameter and fiber 
orientation to mimic the complex organization of cartilage ECM in superficial and middle 
zone respectively. Chondrocytes grew in the two scaffold layers showed different cell 
orientations. Chondrocytes in the electrospun top layer showed parallel orientation to the 
scaffold surface plane while chondrocytes in the bottom phase-separated layer showed 
random orientation. The chondrocytes in the two scaffold layers showed different cell 
morphology, with a more flattened cell morphology in the top layer and a more rounded 
morphology in the bottom layer. The cell densities in the two layers were also different, 
with a higher cell density observed in the top layer than in the bottom layer.  Taken 
together, this anisotropic composite scaffold provides a new strategy in constructing 
complex zonal cartilage tissues. However, further implantation studies are needed to 
investigate the in vivo performance of the bilayered composite scaffolds. 
 
Conclusion 
      We have developed anisotropic composite NF PLLA scaffolds with a electrospun 
NF top layer and a phase-separated macro-porous NF bottom layer. The top layer 
mimicked the cartilage superfacial zone with small pores and more parallel nano-fiber 
orientation. The bottom layer mimicked the cartilage middle zone with a macro-porous 
structure and more random nano-fiber orientation. In vitro chondrogenesis of human bone 
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marrow-derived mesenchymal stem cells study illustrated the promise of this anisotropic 
composite scaffold held in constructing complex zonal cartilage tissues.  
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Fig.6.1. Schematic illustration of the design and fabrication of a nano-fibrous bilayer 
composite scaffold with a top electrospun layer and a bottom macro-porous phase 
separation layer that mimics the architecture of superfacial and middle zone layers of 
articular cartilage tissue. 
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          Fig. 2A                     Fig. 2B                        Fig. 2C   
  
                           Fig. 2D                    Fig. 2E 
  
                          Fig. 2F                     Fig. 2G                      
  
                          Fig. 2H                    Fig. 2I 
 
Fig.6.2. SEM micrographs of composite scaffolds with pre-designed bilayer features. (A-E) 
cross-section: phase-separated layer with small pore size (macro-pore size 125-250 µm) 
with a top electrospun layer of 50 µm (A), 150 µm (B) or 250 µm (C) thickness respectively; 
phase-separated layer with medium pore size (macro-pore size 250-425 µm) (D) or 
phase-separated layer with large-pore size (macro-pore size 425-600 µm) (E) with a top 
electrospun layer of 50 µm thickness. The nano-fibous matrix structure of electrospun 
layer (F, G) and phase-separated layer with small pore size (H, I) observed with different 
magnifications. The electrospun layers were fabricated from 8% PLLA solution. 
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               Fig. 3A                         Fig. 3B                       Fig. 3C 
   
               Fig. 3D                         Fig. 3E                      Fig. 3F 
   
               Fig. 3G                         Fig. 3H                        Fig. 3I 
         Fig 3J 
Fig.6.3. SEM micrographs of cross-section of composite scaffolds with a top electrospun 
layer of different fiber diameters on a medium-pore phase separation layer (250-425 µm). 
(A-C) electrospun layer with small fiber diameter generated from 6% PLLA solution; Fig 
3C was chosen from a bead-free area to show fiber diameter (D-F) electrospun layer with 
medium fiber diameter generated from 8% PLLA solution; (G-I) electrospun layer with 
large fiber diameter generated from 12% PLLA solution. (J) Fiber orientation distribution 
of medium fiber diameter electrospun layer (8%) to the composite scaffold surface plane. 
The fiber angle was defined as an angle between fiber and the scaffold surface plane. 
Fibers having zero degree fiber angle are oriented parallel to the scaffold surface plane. 
Fiber orientation distribution of medium fiber diameter electrospun layer to the composite 
scaffold surface plane. 
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                Fig. 4A                                   Fig. 4B 
 
 
                    Fig. 4C                                Fig. 4D 
 
 
 
Fig.6.4. H-E staining of composite scaffolds after 2wk (A) and 4wk (B) of in vitro 
chondrogenic culture. (C) Quantification of cell numbers in top electrospun layer and 
bottom phase-separated layer of composite scaffolds.  (D) Cell orientation distribution 
inside the top layer. The cell angle was defined as an angle between cell and scaffold 
surface plane. Cells having zero degree fiber angle are oriented parallel to the scaffold 
surface plane. Scale bar: 100 µm. *p<0.05, ** p<0.01. 
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Fig. 5A                                 Fig. 5B 
 
Fig.6.5. Alcian blue staining (A) and Collagen type II immunofluorescence staining (B) of 
cell-scaffold constructs after 4wk of in vitro chondrogenic culture. Green: Collagen type II; 
blue: nuclei.  Scale bar: 100 µm 
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Table 6.1 Fiber diameters of electrospun layer generated with different PLLA 
concentrations 
 
PLLA concentration Fiber diameter(nm) 
6% 155+65 
8% 720+250 
12% 1750+570 
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Chapter 7 
Conclusions and suggestions for future research 
 
Conclusions 
        In this thesis, the fabrication of bioactive nanofibrous PLLA scaffolds and their 
tissue engineering applications have been explored, including inhibiting bacterial growth, 
promoting angiogenesis, chondrogenesis, and osteogenesis. 
        In the first study, a three-dimensional (3-D) porous tissue engineering scaffold was 
developed with the ability to release antibiotics in a controlled fashion for long-term 
inhibition of bacterial growth. The highly soluble antibiotic drug, doxycycline (DOXY), 
was successfully incorporated into PLGA nanospheres using a modified water-in-oil-in-
oil (w/o/o) emulsion method. The PLGA nanospheres (NS) were then incorporated into 
prefabricated nanofibrous PLLA scaffolds with a well interconnected macro-porous 
structure. The release kinetics of DOXY from four different PLGA NS formulations on a 
PLLA scaffold was investigated. DOXY could be released from the NS-scaffolds in a 
locally and temporally controlled manner. The DOXY release is controlled by DOXY 
diffusion out of the NS and is strongly dependent upon the physical and chemical 
properties of the PLGA. While PLGA50-6.5K, PLGA50-64K, and PLGA75-113K NS- 
scaffolds discharge DOXY rapidly with a high initial burst release, PLGA85-142K NS- 
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scaffold can extend the release of DOXY to longer than 6 weeks with a low initial burst 
release. Compared to NS alone, the NS incorporated on a 3-D scaffold significantly 
reduced the initial burst release. In vitro antibacterial tests of PLGA85 NS-scaffold 
demonstrated its ability to inhibit common bacterial growth (S. aureus and E. coli) for a 
prolonged duration.  
        Next, we developed novel tissue engineering scaffolds capable of serving as both a 
three-dimensional (3-D) substrate and a localized and temporally controlled delivery 
vehicle for an angiogenic factor, basic fibroblast growth factor (bFGF) to promote 
cellular activity and stimulate tissue neogenesis. bFGF was first encapsulated into 
poly(lactic-co-glycolic acid) (PLGA) nanospheres (NS) with a double emulsion method 
and then seeded onto a 3-D scaffold. In vitro release results showed that bFGF 
nanospheres incorporated scaffold (NS-scaffold) released bFGF in a temporally 
controlled fashion, which was mainly determined by the chemical and degradation 
properties of the bFGF-containing NS. Results from subcutaneous implantation into mice 
after 4, 7 and 14 days indicated that bFGF released from NS-scaffolds preserved its 
bioactivity, improved cell penetration into scaffolds, and enhanced neovascularization. 
Passive adsorption of bFGF onto the scaffold did not show such positive effects. Results 
from subcutaneous implantation of scaffolds with different PLGA polymer nanospheres 
and with different bFGF dosages into mice after 7 days also indicated that bFGF's 
function depended on its release profile and dosage. The cell penetration and 
neovascularization inside the scaffolds within 7 days were improved with the increase of 
bFGF release rate and dosage (up to the optimal dosage).  
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        Then, we developed a novel PLLA nanofibrous scaffold which can achieve localized dual 
release of BMP-7 and PDGF in a controlled fashion with distinct dosages and release kinetics. 
Both ectopic bone formation and periodontal fenestration defect regeneration on these scaffolds 
were significantly improved over a single release system. The improvement was dependent on the 
dosages, dosage ratio and the release kinetics of the two individual growth factors. This 
nanofibrous scaffold with its controlled multiple growth factor delivery capacity can likely be 
applied to the regeneration of various large sized tissue defects. 
        Last, an anisotropic composite scaffold was fabricated with an upper layer 
mimicking the cartilage superficial zone and a lower layer mimicking the cartilage 
middle zone. The thin superficial layer was fabricated using an electrospinning technique 
to support high density cell growth and more parallel ECM orientation. The lower layer 
was fabricated using a phase-separation technique combined with a porogen templating 
technique to support low density cell growth and a more isotropic ECM orientation. In 
vitro chondrogenesis of human bone marrow-derived mesenchymal stem cells (hMSCs) 
study illustrated the promising application of the composite scaffold to direct the 
formation of an anisotropic tissue structure that resembles the natural articular cartilage 
superficial and middle zones. 
 
Future work 
        There are a number of interesting future directions this research could lead to. This 
thesis has already showed that nanofibrous PLLA scaffolds with the dual release of 
BMP-7 and PDGF could synergistically promote neo-bone formation and periodontal 
defect repair than scaffold with the release of either growth factor alone. It would be 
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interesting to apply this BMP-7 and PDGF dual release bioactive scaffold system to other 
bigger bone defect models. 
        This thesis also showed that nanofibrous PLLA scaffold with the introduction of 
controlled release of doxycycline could inhibit bacterial growth over a prolonged time 
period. It would be of interest to combine three biological factor (BMP, PDGF, 
doxycycline) release systems into PLLA scaffolds. PDGF is capable to promote 
angiogenesis, BMP-7 is capable to promote osteogenesis and doxycycline is capable to 
inhibit both bacterial infection and matrix metalloproteinases (MMPs). These three 
factors with suitable individual release profiles and dosages from PLLA nanofibrous 
scaffolds could function synergistically and result in improved bone regeneration in 
defects.   
        Additionally, this thesis showed  that an anisotropic composite scaffold fabricated 
using the combination of electrospinning and phase separation techniques could mimic 
the zonal structure of cartilage. The composite scaffold can be further examined for 
cartilage tissue regeneration using animal models. With further improvement on the 
fabrication technologies, the composite concept could be extended to regenerate more 
complex tissues such as osteochondral interface structure. 
 
 
